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1 1   INTRODUCTION 
 
 
1.1 Mechanisms of inflammation 
 
The mammalian organism faces a lot of chemical and biological invaders such as viruses, 
bacteria, fungi or even body own cancer like cells. The reaction of the organism against these 
pathogens often results in a process called inflammation, which is characterised through signs 
of heat (calor), pain (dolor), redness (rubor), swelling (tumor) and dysfunction (functio laesa). 
Inflammation is a protective response of the immune system to remove injurious or infectious 
agents. Acute inflammation can result in initiation of tissue repair or in a chronic 
inflammatory process characterized by an active inflammation and simultaneously occurring 
tissue repair and destruction.  
 
Inflammatory reactions are controlled by the immune system, a network of organs, different 
cells types and molecules. The immune system itself can be divided into two major branches 
the innate and the adaptive system, which can be further subdivided into a humoral and a 
cellular branch1. The adaptive immune system contains more specialised lymphoid cells, 
whereas the innate system consist of several distinct components ranging from the barrier 
functions of the epithelia as well as cells and molecules able to control or destroy pathogens 
once they have overcome the epithelial defence. Within the first hours, defence is mediated by 
resident macrophages within the tissue and subsequent recruitment of neutrophils and 
monocytes. The monocytes then further differentiate into phagocytotic cells in order to kill 
microbial invasive pathogens. 
Molecules involved in the inflammatory reactions are classified into pro- and anti-
inflammatory molecules. These are soluble cytokines, like several interleukins (IL), 
interferons (IFN), growth factors and chemotatic cytokines, also known as chemokines2-5.   
 
 
Leukocyte recruitment to areas of inflammation 
A crucial step in the process of inflammation is the recruitment of leukocytes from blood 
vessel towards the inflamed tissue, a process known to occur in multi steps6-9 (Fig. 1-1). The 
process starts with the selectin-mediated initial rolling of the leukocytes along the blood 
vessel wall. These leukocytes are then activated upon binding of chemotatic cytokines 
(chemokines) presented on the endothelium. This leads to firm adhesion characterised by 
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binding of activated leukocytes via their integrins to cellular adhesion molecules. Finally, 
transmigration of the leukocytes across the endothelial cell layer occurs, which is regulated by 
several molecules of the tight junctions. This series of events can be observed for neutrophils, 
lymphocytes and monocytes, although the molecules involved are different among the 
leukocyte subpopulations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-1: Leukocyte recruitment to inflamed tissue10 
An initial contact of the leukocyte to the endothelium is mediated by binding of the endothelial 
selectins (E-, P-selectin) to sialyl-lewisX glycoproteins (PSGL-1) on leukocytes. The binding is 
reversible and therefore leading to the rolling of the leukocyte on the endothelium. Binding to 
chemokines presented by proteoglycans (HSPG) and binding of chemokine activated leukocyte 
integrins (LFA-1) to cellular adhesion molecules (VCAMs) lead to firm adhesion. Finally, 
transmigration of the leukocyte across the endothial cells is regulated by cellular junction 
molecules (VE-cadherin) towards the inflammatory stimulus. 
  
 
The initial rolling and attaching of leukocytes to the endothelial cell layer is mediated by 
binding of the selectins to their ligands. On inflamed endothelial cells P- or E-selectins are 
upregulated by tumor necrosis factor (TNF)-α and interferon (IFN)-γ and bind to the sialyl-
lewisX glycosylated P-selectin glycoprotein ligand-1 (PSGL-1) expressed on neutrophils and 
monocytes11-13. In contrast to E- and P-selectin, L-selectin is expressed on leukocytes and was 
shown to be involved in the rolling14. The selectin-ligand binding is reversible due to the 
weak binding affinity of the selectins to the sialyl-lewisx residues on PSGL-1 resulting in 
further cell rolling onto the endothelial cell layer.  
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After the initial rolling leukocytes are activated upon binding of chemokines presented by 
endothelial cells via heparin sulphate proteoglycans (HSPG). These chemokines are cytokines 
leading also to directional chemotatic migration of cells (chemotaxis) and are different for the 
leukocyte subpopulations.  
The activation of leukocytes by chemokines then leads to firm adhesion, which is 
characterised by the interaction of cellular adhesion molecules, expressed on the endothelial 
cells, with activated β1- and β2-integrins, expressed on leukocytes. Important integrins are the 
lymphocyte function-associated antigen-1 (LFA-1) and the Mac-1 (CD11b/CD18) both 
expressed on neutrophils and monocytes. The LFA-1 antigen  interacts with the inter-cellular 
adhesion molecule-2 (ICAM-2)15,16, whereas Mac-1 interacts with the intercellular adhesion 
molecule-1 (ICAM-1)17-19 Additional interactions take place between the monocyte expressed 
very late antigen-4 (VLA-4) and the vascular cell adhesion molecule-1 (VCAM-1)20,21.  
The final step of the leukocyte recruitment process is known as transmigration. Within this 
process leukocytes transmigrate across the activated endothelial cell layer towards a 
chemoattractant or chemokine22,23. Additionally, it was shown, that depending on leukocyte-
subtype or tissue specificity, leukocytes can transmigrate through cellular tight junctions 
(paracellular) or channels within the cell itself (transcellular)24. Various interactions of the 
cellular junction molecules with molecules expressed by leukocytes have been described. For 
the neutrophils homophilic interactions of the platelet-endothelial cell adhesion molecule-1 
(PECAM-1, CD31) have been shown to be critical for crossing the cellular tight junctions25. 
The monocyte transmigration was supposed to be regulated by PECAM-1 interactions25, by 
interactions of the junctional adhesion molecules (JAM)-A and C and by CD9926-29. These 
interactions for example can be homophilic in case of PECAM-1, CD99 or JAM-A or 
heterophilic for example in case of LFA-1/JAM-A. PECAM-1, CD99 and JAM-A 
interactions can occur between the leukocytes and the endothelial cells or between two 
endothelial cells. Further molecules like the vascular endothelial (VE)-cadherin are also 
reported to be involved in the vascular permeability and therefore in the regulation of the 
transmigration process30,31. 
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1.2 Chemokines and their receptors 
 
1.2.1 Classification and structure of chemokines 
 
More than 50 chemokines have already been described. They are cytokines directing 
leukocytes to the area of inflammation via a chemotatic stimulus32,33. They are structurally 
subdivided into four classes, depending on the N-terminal location of the first or first two 
cysteine residues (Fig. 1-2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-2: Schematic structure of chemokine classes 
Chemokines are classified into four groups depending on the location of the first or the first two N-terminal 
residues. There exists either as XC-, CC-, CXC- or CX3C-chemokine. The CX3C chemokine are the only 
transmembrane expressed member of this family, since the contain an chemokine domain, a mucin-like 
domain, a transmembrane region (TM) and a intracellular cytoplasmic tail (CT). The peptide chain of all 
chemokines is indicated in blue. 
 
 
 
XC-chemokines contain only one cysteine residue. Members of this group are lymphotactin-
alpha (XCL1) and lymphotactin-beta (XCL2), whose receptor XCR1 is expressed on T-
lymphocytes and is therefore also responsible for their recruitment to the thymus34,35.  
The second group consists of chemokines containing two adjacent cysteine residues, they are 
called CC-chemokines. The group consists of at least 28 distinct chemokines. Members of 
this family are the monocyte chemoattractant protein-1 or the chemokine CCL5 (RANTES, 
regulated on activation normal T cell expressed)36,37.  
The CXC-chemokines represent another group of so far 17 dintinct members, which are 
characterised by an acid flanked by two cysteine residues (CXC). The best characterised 
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member of this group is IL-8 (CXCL8) attracting neutrophils and monocytes38,39. It is induced 
by proinflammatory cytokines IL-1, TNF-α and even by lipopolysaccharide (LPS)32.  
The fourth group of chemokines, the CX3C-chemokines, consists of one member (fractalkine 
(FKN), CX3CL1) and is characterised through three random amino acids flanked by one 
cysteine residue on both sides. 
 
In contrast to the structural classification, chemokines can additionally be classified according 
to their function and physiology. They can be divided into pro-inflammatory (inducible) or 
homeostatic (constitutive) chemokines or into dual chemokines, if they are acting in both 
ways. Inducible chemokines normally act on monocytes, granulocytes and T-cells in order to 
recruit cells to areas of inflammation or infection. In contrast, constitutive chemokines 
normally act on leukocytes in absence of inflammation, for example in haematopoiesis in 
order to regulate the trafficking of these leukocytes within primary (bone marrow and thymus) 
and secondary (lymph nodes and peyer’s patches) lymphatic organs33,40.  
 
Most of the chemokines are soluble proteins with a molecular weight of 8-10 kDa41. They 
share high nucleic and amino acid homology and are structurally organised in a so called 
Greek key shape structure, stabilised through disulfide bonds. Chemokines consist of a signal 
peptide (20 amino acids), an N-terminal loop (N-loop), a single-turn helix (310-helix) and 
three β-strands followed by an α-helix42.  
 
 
1.2.2 Structure and signal transduction of chemokine receptors 
 
The approximately 20 described chemokine receptors share the same nomenclature with the 
chemokines, however, they are abbreviated with L (for ligand) and receptors with R (for 
receptors). The XC-, CC-, CXC- and CX3C-chemokine receptors exclusively bind the 
chemokine ligands of the analogous groups43-45. Many of these receptors are able to bind more 
than one chemokine of this groups, which then can lead to different signalling events46.  
The chemokine receptors exist as homo- and heterodimers with a size of approximately 40 
kDa and belong to the class of G-protein coupled (GPCRs) receptors47. Structurally, these 
type-I transmembrane proteins consist of seven transmembrane α-helices, which are 
connected through three intra- and three extracellular hydrophilic loops.  
The N-terminal loop is involved in ligand binding48, whereas the cytoplasmic C-terminal tail 
contains serine and therione residues as potential phosphorylation sites, which are important 
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for the regulation of the receptor activity49,50. The receptor activation is a cascade of 
chemokine binding, conformational changes and G-protein activation. Further downstream 
involved molecules are for example phospholipases C (PLC), phosphatidylinositol 
bisphosphates (PIP2), inositol triphosphate (IP3) and proteinkinase C (PKC), which then can 
activate MAP-Kinase cascades by phosphorylation leading to the activation of extracellular 
signal-regulated kinases (ERK) or p3849,51.  
 
 
1.3 Transmembrane chemokines 
 
1.3.1 The transmembrane chemokine CX3CL1 
 
Among the large family of chemokines, there is an exceptional member existing as a soluble 
and as a membrane-associated form. This transmembrane CX3C-chemokine CX3CL1 is also 
known as fractalkine52 or neurotactin53. The human CX3CL1 gene encods a protein of 397 
amino acids and is located on chromosome 16q13, whereas the mouse gene encodes a protein 
of 395 amino acids and is located on chromosome 8 46.0. Human and mouse CX3CL1 share 
great sequence and structural homology. The schematic structure of human and mouse 
CX3CL1 is shown in Fig. 1-3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-3: Schematic structure of human and mouse CX3CL1 
The domain structures [B], indicated by the starting amino acid, of human and mouse CX3CL1 
and the structure of CX3CL1 within the membrane [B] are shown. Both transmembrane 
chemokines contain a signal peptide (light grey), an N-terminal chemokine domain (green), a 
highly glycosylated mucin-like stalk (dark grey), a transmembrane domain and a C-terminal 
cytoplamic tail (blue) containing a potential SH2-domain binding motif (YVLV).  
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Both proteins contain a signal peptide (24 amino acids), an N-terminal CX3C-chemokine 
domain (76 amino acids) attached to a highly o-glycosylated mucin-like stalk region (241 
amino acids (human) / 239 amino acids (mice)), a transmembrane domain (21 amino acids) 
and a C-terminal cytoplasmic tail (35 amino acids). This tail contains a potential tyrosine 
phosphorylation site (YVLV) similar to other SH2-domain binding sites, predicted to bind 
clathrin-coated pit associated cargo adaptor protein AP254. The mucin-like stalk was reported 
to contain 17 degenerated mucin-like repeats with 26 potential O-glycosylations at serine and 
threonine residues52,55,56.  
The transmembrane chemokine CX3CL1 is expressed in the membrane, but also exists as a 
soluble form consisting of the chemokine domain plus the mucin-like stalk (approximately 70 
kDa)52,53. 
According to the studies with epithelial cell lines, CX3CL1 is expressed in two cellular 
compartments: on the cell membrane and in distinct subcellular compartments. Intracellular 
CX3CL1 was associated with soluble N-ethylmaleimide factor attachment protein receptor 
(SNARE) proteins like syntaxin-13 and VAMP-3, pointing towards SNARE-mediated rapid 
recycling of CX3CL1 to and from the endomembrane storage compartments57.  
 
CX3CL1 was reported to be expressed by various cells and tissues58. High levels of 
constitutive and LPS-induced expressions were found in the brain53,59. Lower levels were 
found in the heart, the lung, the kidney and the intestine52. As shown by in vitro studies 
CX3CL1 is constitutively expressed on epithelial cells, but not on endothelial cells and not on 
circulating peripheral blood mononuclear cells (PBMCs)52,53,60.  
Several studies described the induction of CX3CL1 by various cytokines during inflammation 
in different cell types. Endothelial cells for example upregulate CX3CL1 after TNF-α and IL-
1 or TNF-α and IFN-γ stimulation52,61. In airway smooth muscle cells CX3CL1 is also 
upregulated by TNF-α and IFN-γ62, whereas in aortic smooth muscle cells CX3CL1 
expression could be increased by TNF-α and IL-1β63,64. Fibroblasts express elevated levels of 
CX3CL1 after combinatorial treatment with TNF-α and IL-865. Studies investigating a 
potential negative effect of cytokines on CX3CL1 expression revealed that in endothelial cells 
the soluble interleukin-6 receptor-α inhibits the expression CX3CL166 and that in airway 
smooth muscle cells TGF-β treatment suppresses CX3CL1 expression effectively62. Thus, 
CX3CL1 seems to be tightly regulated by pro-and anti-inflammatory cytokines. 
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1.3.2 The function of CX3CL1-CX3CR1 interaction 
 
CX3CR1 exclusively binds to CX3CL1. It was first described as a G-protein coupled receptor 
and named CMKBRL or V2867,68. The gene contains 4 exons and is localised on the human 
chromosome 3p21.3 and the mouse chromosome 9 F4. Like all chemokine receptors, 
CX3CR1 is a G-protein coupled seven transmembrane-spanning domain receptor. 
CX3CR1 is expressed on leukocytes like human monocytes69, T cells70, NK-cells71,72, 
dendritic cells73 and throughout the brain on astrocytes and microglia53,74. The endogenous 
CX3CR1 receptor expression can be increased/decreased by treatment of NK-cells and human 
periphal blood mononuclear cells (PBMCs) with IL-2 and IL-1575-77. 
 
CX3CL1 was thought to have two functions within the process of leukocyte recruitment. It 
was shown that CX3CL1 expressed on the cell membrane mediates adhesion of cells carrying 
the CX3CR1 receptor. On the other hand, it was shown that soluble CX3CL1 induces 
chemotaxis. Studies, in which the chemokine domain or the mucin-like stalk region were 
mutated, supported the assumption that CX3CL1 is involved in the adhesion of leukocytes. 
Although the exchange of the CX3C-chemokine domain to that of IL-8, MCP-1 or RANTES 
for example showed that adhesion was not disturbed and occurs to an equivalent extend 
compared to the wt CX3CL1, the flow adhesion activity of the various chimera compared to 
the wt CX3CL1 was, however, efficiently decreased. Binding studies of wt CX3CL1 to the 
CX3CR1 receptor revealed a slower off-rate for wt CX3CL1 as for the chimeras, supporting 
the previous findings of decreased flow adhesion. Interestingly, cells captured by CX3CL1 
showed no rolling capacity, whereas cells captured by the IL-8 and MCP-1 chimeras 
displayed the rolling78. Mutational studies on the chemokine domain revealed two residues at 
position seven (lysine) and 47 (arginine) of the protein being differently associated with 
adhesion and transmigration/chemotaxis. Both K7A and R47A showed a massive decrease in 
the binding affinity to CX3CR1 and therefore a reduced firm adhesion of CX3CR1-
expressing cells under flow conditions79. The analysis of the mucin-like stalk, in which the 
entire mucin-like stalk was changed by that of rod-like segments of E-selection resulted in 
similar adhesion of PBMCs compared to the wt CX3CL1, indicating the importance of the 
chemokine domain receptor interaction for the adhesion process80.  
 
In vivo studies on human and mouse receptor CX3CR1 revealed that the receptor is involved 
adhesion and transmigration71,81,82. The CX3CR1/CX3CL1 interaction occurs under 
physiological flow conditions and is independent of the G-protein activation52,71,83,84. More 
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recent studies , however, showed that Gi-protein signalling is associated with leukocytes85. 
Studies with double CX3CR1-/- and ApoE-/- animals showed reduced lesion size due to 
disordered macrophage accumulation86,87. In the brain of CX3CR1-/- animals microglial 
neurotoxicity is increased compared to control animals due to enhanced neuronal cell loss88. 
In CX3CR1-deficient mice reduced kidney fibrosis, reduced inflammation in the ischemia 
reperfusion injury, as well as reduced clearance of enteroinvasive bacteria was observed89,90. 
Genetic studies on CX3CR1 revealed the existents of two single nucleotide polymorphisms 
(SNP) in the fourth exon of the gene91,92. The V249I-SNP and the T280M-SNP were 
demonstrated to be associated with reduced risk of atherosclerotic cardiovascular diseases 
(CVD), due to the reduced binding affinity of the I249 and M280 receptor variants to 
CX3CL1 resulting in reduced  of primary leukocytes93-95.  
The role of the chemokine CX3CL1 during inflammatory processes was also investigated in 
in vivo models. The first described in vivo study of the CX3CL1 knockout, however, showed 
no influence of CX3CL1 in inflammatory models, contrarily to the previous data raised with 
neutralising antibodies96. Studies of CX3CL1 in double knockout models with ApoE and 
CCR2 deficient mice then revealed the atherogenic accomplishment of CX3CL1 in the 
brachiocephalic artery97 and its capacity in the process of macrophage accumulation during 
inflammation98. Increased CX3CL1 accumulation was also seen in atherosclerotic coronary 
arteries within the intima, media and adventitia99. In the brain of CX3CL1 knockout mice a 
reduced infarction size and a reduced mortality in the model of cerebral ischemia reperfusion 
injury was described100. Due to the high expression of CX3CL1 in the lung, a possible 
association of CX3CL1 with lung diseases was investigated. One worldwide advancing lung 
disease is COPD (chronic obstructive pulmonary disease) a chronic airway inflammation, 
which is mainly caused by cigarette smoking. Studies with mice chronically exposed to 
cigarette smoke, showed increased CX3CL1 expression101.  
 
 
 
1.4 Proteolytic cleavage by ADAM proteins 
 
1.4.1 The family of ADAM proteins 
 
The family of ADAM proteins (ADAM, “A Disintegrin and a Metalloproteinase”) contains 
proteins with a size of 750-800 amino acids. Together with the snake venom 
metalloproteinases (SVMPs) they are part of adamlysins, a subfamily of the metzincin 
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enzyme superfamily. This metzincin superfamily also contains matrixins (matrix 
metalloproteinases (MMPs)), serralysins and astacins102. A key feature of zinc-dependent 
metzincins is the zinc-binding consensus sequence (HEXXH) and the proximal to the 
catalytic core located conserved methionin residues (Met-turn)103,104.  
Approximately 40 cDNA sequences of the ADAMs containing a conserved metalloproteinase 
domain were identified in a broad spectrum of organisms. However, only approximately 15 of 
those have the HEXXH zinc-binding sequence, indicating that not all ADAMs are 
catalytically active105,106. Structurally one domain of the ADAMs is similar to disintegrins. 
These disintegrins are snake venom polypeptides that are able to bind to platelet integrin 
leading to inhibited platelet aggregation by integrin disruption107,108.  
Most of the ADAMs are type-1 transmembrane glycoproteins and are characterised by an N-
terminal signal sequence, a prodomain, a metalloproteinase domain, a disintegrin domain, a 
cyteine-rich region containing epidermal growth factor (EGF) repeats, a transmembrane 
domain and a cytoplasmic tail109-111 (Fig. 1-4). Some ADAMs, however, are soluble proteins 
containing thrombospondin type-I motif and are therefore named “a disintegrin and a 
metalloproteinase with thrombospondin motifs” (ADAM-TS). This type of ADAMS can bind 
proteins of the extracellular matrix112. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-4: The schematic structure of ADAM proteins113 
A typical structure of a disintegrin and metalloproteinase is shown containing a cytoplasmic tail, 
a transmembrane region, a cysteine-rich region (yellow) with EGF-repeat (blue), a disintegrin 
domain (green) and a catalytic metalloproteinase domain (red). A prodomain (grey) is also 
attached to the catalytic domain leading to an inactive proteinase by binding to the His3-Zinc-
Cysteine complex within the catalytic centre of the ADAM. The metalloproteinase is activated by 
a removal of the cysteine (“cysteine-switch”) from the complex or by an enzymatic elimination of 
the prodomain through furin convertases.  
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The extracellular domains (ectodomains) of several proteins like growth factors, cell adhesion 
molecules, cytokines, receptors and other transmembrane proteins can be proteolytically 
cleaved from the surface leading to the release of its soluble ectodomain105, a process termed 
“ectodomain shedding”.  The ectodomain shedding is performed in part by activated ADAM 
proteins. ADAMs themselves can be activated by a “cysteine-switch” leading to the removal 
of the intermolecular complex within catalytic centre of the ADAMs. The intermolecular 
complex is formed by the interaction of a single cysteine residue of the prodomain and the 
zinc atom of the metalloproteinase domain114. It is known that during the process of shedding 
the ADAMs hydrolyse their substrates by transferring water molecules onto the metal ion 
(Zn++). The cleavage sites for ADAMs are highly variable and consensus sequences could not 
be defined115,116. ADAMs can also be activated by an enzymatic cleavage of the prodomain by 
furin-peptidases117. Moreover, it was suggested that ADAM activation can be regulated by 
(post)-transcriptional control, ADAM mRNA stability, cytosolic interaction or even cellular 
and membrane distributions118.  
 
ADAMs were found to be ubiquitously distributed within the mammalian organism110,111. 
They were first described to be involved in the reproduction process, in particular in the 
spermatogenesis and the fusion of the sperm and the egg and therefore named fertilin-α and -β 
(ADAM1 and ADAM2)109,110,119. As already mentioned, the family of ADAM proteins 
consist of about 15 catalytically active members. Examples are meltrin-γ (ADAM9), 
kuzbanian (ADAM10), meltrin-α (ADAM12) or the tumor-necrosis factor-α (TNF-α) 
converting enzyme (TACE, ADAM17). They were reported to be involved in the 
development of the muscles, the bones, the brain and also in the development of inflammatory 
processes120-126.  
 
 
1.4.2 ADAM10, ADAM17 and their substrates in inflammatory processes 
 
ADAM10 and ADAM17 are involved in many neuronal, tumor and inflammation associated 
diseases127. In the central nervous system (CNS) ADAM10- and/or ADAM17-mediated 
shedding of the amyloid precursor protein (APP) and the prion protein (PrP) leads to 
neuroprotection128-132, whereas shedding-induced signalling of the receptor Notch increases 
neurogenesis133,134.  
In inflammatory processes, ADAM17 is involved in the shedding of the pro-inflammatory 
cytokine TNF-α120,122 and its receptor TNFR135, which represents together with IL-1 and its 
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receptor IL-1R one of the major pro-inflammatory cytokines/receptor pairs. The pro-
inflammatory IL-6 receptor (IL-6R) was also shown to be shed by ADAM17136. ADAM17 
was furthermore described in the release of cell adhesion molecules like L-selectin137,138, 
VCAM-1139,140 and also CX3CL1141,142.  
ADAM10 was first isolated from myelin membranes of the brain143 and since then shown to 
be involved in several inflammatory processes. For example ADAM10 releases the sialyl-
lewisX PSGL-1 ligand for E- and P-selectin from the surface of leukocytes144. Furthermore 
ADAM10 was made responsible for the release of the vascular endothelial (VE)-cadherin 
and the transmembrane chemokine CX3CL1145,146.  
Several ADAM10- and ADAM17-mediated shedding events were identified by the use of the 
dual-specific inhibitor for ADAM10 and ADAM17 (GW280264 (A10/17)) and the specific 
inhibitor for ADAM10 (GI254023 (A10)), which block the catalytic centre within the 
metalloproteinase domain. The dual-specific A10/17 inhibitor was reported to have an IC50 
against ADAM17 of 8.0 nM and an IC50 of 11.5 nM against ADAM10, whereas the specific 
A10 inhibitor was reported to have an IC50 against ADAM10 of 5.3 nM146.  
 
 
1.4.3 Shedding of CX3CL1 by ADAM10 and ADAM17 
 
The transmembrane chemokine CX3CL1 exists as a membrane-bound form and as a smaller 
soluble forms presented as the CX3C-chemokine domain plus the mucin-like stalk 
(approximately 70 kDa)52,53. Since the soluble forms of CX3CL1 were reported to be smaller 
as the membrane-bound forms, a proteolytic cleavage process from the cell surface was 
proposed. ADAM10 and ADAM17 were likely to be responsible for the release of soluble 
CX3CL1. 
In fact, studies showed that ADAM10 and ADAM17 are involved the process of CX3CL1 
shedding. ADAM17 is involved in the PMA-induced shedding of CX3CL1141, whereas 
ADAM10 is involved in the process of constitutive and ionomycin-induced shedding of 
CX3CL1146, processes which were both pharmacologically targeted by the use of the specific 
ADAM10 inhibitor (A10, GI254023) and the dual-specific ADAM10 and ADAM17 
inhibitor (A10/17, GW280264) (Fig. 1-5).  
Although an involvement of other proteinases in the cleavage of CX3CL1 can be assumed, 
no specific proteinase was shown so far to be part of the CX3CL1 shedding127. As already 
mentioned, CX3CL1 is shed from the cell surface proximal to the membrane by ADAM10 
and by ADAM17. The di-argine (R-R) motif, located at amino acid position 2-3 distal from 
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the membrane within the mucin-like stalk region of CX3CL1, was predicted to represent the 
cleavage site52. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-5: Ectodomain  shedding of CX3CL1 by ADAM10 and ADAM17 
ADAM10 constutively cleaves CX3CL1 from the surface, whereas ADAM17 cleaves 
CX3CL1 from the surface by an induction of PMA. Cleavage within the mucin-like stalk of 
CX3CL1 occurs proximal to the membrane resulting in soluble forms of CX3CL1 and 
different C-terminal fragments (CTFs), which are then further degraded by the membrane 
associated secretases and the proteasome. This cleavage can be pharmacologically targeted 
by the high affinity hydroxamic acid inhibitors A10 (GI254023X) and A10/17 
(GW280264X), which contain hydrogen, lower alkyl, lipophilic and heteroaryl 
substituents63.  
 
 
The catalytic site of the ADAMs is located in the metalloproteinase domain, far distal from 
the membrane. However, the process of shedding was described to be proximal to the 
membrane, so that one can conclude that the structure of the ADAMs must be very flexible. 
Indeed, current findings on the structural organisation of the protein support this view113. 
Not only the structure of the ADAMs is important for the function as a proteinase, 
moreover structural requirements and interaction with other molecules like tetraspanins are 
addressed in current studies147,148.  
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1.5 Issues and aims 
 
The transmembrane chemokine CX3CL1 contributes to leukocyte adhesion and thereby 
promotes the development of inflammatory diseases. Regulation of the CX3CL1 function, in 
particular shedding, appears to be mainly controlled by ADAM10- and ADAM17-dependent 
mechanisms. Up to date, it is not fully clear how ADAM10 and ADAM17 contribute to 
CX3CL1 function. Molecular determinants within CX3CL1 that influence its shedding and 
function remain to be clarified.  
 
The goal of this thesis is to understand and to characterise the molecular determinants for the 
CX3CL1 function, in particular shedding by ADAM10 and ADAM17, and to further 
characterise the CX3CL1 function in processes of adhesion and transmigration. The results 
should help to extend the current understandings of the inflammatory leukocyte recruitment. 
To achieve this, the specific aims of this thesis are as follows. 
 
 
1. Compare shedding of human and mouse CX3CL1 mediated by ADAM10 
(and ADAM17). 
 
2. Study the determinants within mouse CX3CL1 for ADAM10-mediated 
shedding by generation of mouse CX3CL1 chimeras/variants, with 
changes in the N-terminal region, the membrane proximal region and the 
C-terminal region.  
 
3. Analyse the functional properties of the mouse CX3CL1 chimeras/variants 
in terms of cellular trafficking, surface expression, adhesion and 
transmigration. 
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2 2   MATERIALS AND METHODS 
 
 
2.1 Chemicals and reagents 
 
All reagents were of analytical grade and purchased from mayor chemical suppliers such as 
Sigma-Aldrich Chemie GmbH (Steinheim, Germany), Carl Roth GmbH + Co. KG 
(Karlsruhe, Germany) and Merck KGaA (Darmstadt, Germany) unless otherwise stated in the 
text.  
All enzymes described were mainly purchased from Fermentas GmbH (St. Leon-Rot, 
Germany) and Invitrogen GmbH (Karlsruhe, Germany). Oligonucleotides were purchased 
from MWG Biotech AG (Ebersberg, Germany), antibodies and cytokines mainly from R&D 
Systems GmbH (Wiesbaden-Nordenstadt, Germany) and PeproTech GmbH (Hamburg, 
Germany) and cell culture solutions mainly from PAA Laboratories GmbH (Pasching, 
Austria). Expression vectors were made on the basis of the pcDNA3.1(+) from the Invitrogen 
GmbH. 
The specific ADAM10 (GI 254023X) inhibitor and dual-specific ADAM10 and ADAM17 
inhibitor (GW 280264X) were kindly provided by Dr. Neil Brodway, GlaxoSmithKline 
(Stevenage, UK). The inhibitors were described in US patents US 6 172 064, US 6 191 150, 
and US 6 329 400. 
Unless otherwise stated in the text methods were used according to Sambrook and Russell149.  
 
 
2.2 Molecular biology 
 
2.2.1 RNA isolation and synthesis of cDNA 
 
Mice were sacrificed by cervical dislocation, the spleen was removed and snap frozen in 
liquid nitrogen before being homogenized, separated and precipitated using a modified trizol 
protocol from Invitrogen. Briefly, 1ml trizol reagent (Invitrogen GmbH) was mixed with 100 
mg tissue and incubated at 15-30°C for 5 min. Then 200 µl of chloroform was added, mixed 
vigorously and again incubated at 15-30°C for 5 min. The colourless upper aqueous phase 
was taken and precipitated with 0.5 ml of 100% isopropanol by incubating for another 10 min 
at 15-30°C and centrifugation at 16,100 g for 10 min at 4°C. The supernatant was discarded 
 
16      Chapter 2 
and the RNA-pellet was washed twice with 70% EtOH, air dried and dissolved in 10-20 µl of 
ultra pure H2O. Total RNA concentrations were measured by reading the absorbance at 260 
nm in a standard spectrometer (Nano-Drop NP-1000, Thermo Scientific, Waltham, USA).  
1-5 µg of total spleen RNA was then subjected to DNase treatment by adding 1 µl of RNase-
free DNase in a 10 µl reaction mixture containing 1x reaction buffer with MgCl2 and ultra 
pure H2O (aqua ad injectabilia, Delta Select GmbH, Pfullingen, Germany). After an 
incubation at 37°C for 30 min, the enzymes were inactivated by an incubation for 5 min at 
70°C. After a brief incubation on ice, the RNA was subjected to 1st strand cDNA synthesis 
using the RevertAid™ first-strand cDNA-synthesis kit protocol (Fermentas GmbH). Briefly, 
5 µl of DNase treated RNA and 0.5 µg oligo(dT)18 primer were solved in ultra pure H20 to a 
volume of 12 µl, incubated for 5 min at 70°C and then briefly incubated on ice. 1 x reaction 
buffer, 20 U RNase inhibitor and 2 µl of 10 mM dNTP mix were added. After an incubation 
at 37°C for 5 min, 200 U of RevertAid™ M-MuLV reverse transcriptase was added to a final 
volume of 20 µl and incubated at 42°C for 60 min. The reaction was heat-inactivated for 10 
min at 70°C. Subsequently, 2 µl of this reaction mixture containing the reversely transcribed 
cDNA was used as template in a standard PCR. 
 
 
2.2.2 Polymerase chain reaction 
 
The polymerase chain reaction (PCR) was performed in a standard thermocycler 
(TProfessional) from Biometra biomedizische Analytik GmbH (Goettingen, Germany) for 3 
min at 94°C, followed by 25-35 cycles of 30-60 s at 94°C, 30-45 s at 42-65°C, 45-60 s at 68 
or 72°C and a final extension with 5 min at 72°C. The reaction mixture contained 1x PCR 
buffer, 1-4 mM MgCl2 or MgSO4, 0.1-0.2 mM dATP, dCTP, dGTP and dTTP, 0.2 µM primer 
sense, 0.2 µM primer antisense, 10-200 ng DNA template or 2 µl of cDNA template, 1-5 U 
polymerase and was solved in ultra pure H2O to a final volume of 50µl. Taq-polymerase, Pfx-
platinum-polymerase or Pfu-polymerase) were used with specific 10x PCR buffers. 
 
Primers 
5mFKNEcoRI_fo 5‘ TCCGGAATTCGCCACCATGGCTCCCTC 
GCCGCTC 3‘  
Sense primer to amplify the mCX3CL1 or 
mCX3CL1/CD4 genes 
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3mFKNXhoI_re 5‘ ATCCGCTCGAGTCACACTGGCACC 
AGGACGTATG 3‘ 
Antisense primer to amplify the mCX3CL1 gene 
   
  5hRANEcoRI_fo 5‘ GAATTCGCCACCATGAAGGTCTCC 3‘ 
Sense primer to amplify the CCL5 gene 
 
                 3hRANAgeI_re 5‘ ACCGGTGCTCATCTCCAAAGAGTTGAT 3‘ 
Antisense primer to amplify the CCL5 gene   
  
  5mFKNAgeI_fo 5‘ ACCGGTGGCAAGTTTGAGAAGCGG 3‘  
Sense primer to amplify the upper part of the mCX3CL1 
stalk region 
   
  3mFKNPflAge_re 5‘ ACCGGTCCAAACGGTGGTGGAGATG 3‘     
Antisense primer to amplify the upper part of the 
mCX3CL1 stalk region 
 
  5mCD4EcoRI_fo  5‘ GAATTCGCCACCATGTGCCGAGCCATC  3‘ 
Sense primer to amplify the mCD4 gene 
  
3mCD4XhoI_re 5‘ TCGAGTCAGATGAGATTATGGCTC 
TTCTGCATC  3‘  
Antisense primer to amplify the mCD4 gene 
  
  3mFKNCD4Bam_re 5‘ TGGATCCTGGAGTCCATC 3‘           
Antisense primer to amplify the mCX3CL1/CD4 gene 
 
  5mFKNPfl_fo  5‘ ACCACCGTTTGGCCGAGT  3‘  
Sense primer to amplify the truncated form of the 
mCX3CL1 or mCX3CL1/CD4 genes 
 
 
 
 
18      Chapter 2 
  3mFKNStopl_re 5‘ CTCGAGTCAGCTCTGGTAAGCAAACATGGC  3‘ 
Antisense primer to amplify the truncated form of the 
mCX3CL1 or mCX3CL1/CD4 genes 
 
 
2.2.3 Agarose gel electrophoresis and DNA-purification 
 
The agarose gel electrophoresis was performed in an Agagel Mini or Midi-Wide apparatus 
from Biometra biomedizinische Analytik GmbH for 30-60 min at 40-120 V (Power pac 200, 
Bio-Rad, USA). DNA-samples were loaded with 6x DNA loading dye and 6x Orange DNA 
loading dye (Fermentas GmbH) and separated in a 1-2% (w/v) standard agarose gel (Biozym 
Scientific GmbH, Hess. Oldendorf, Germany) containing 1 µg/ml ethidium bromide in TAE 
buffer (40 mM Tris-Acetate, 1 mM EDTA). The GeneRuler 1kb –or 100 bp DNA Ladder or 
the MassRulerTM high -or low range DNA ladder (Fermentas GmbH) were used as standards. 
Subsequently, the DNA of interest was excised from the gel using a scalpel blade and was 
then purified using the NucleoSpin® extract II kit (Machete-Nagel GmbH & Co. KG, Dueren, 
Germany) according to manufacturer’s instructions. Briefly, the gel slice was incubated at 
50°C for 10 min in two volumes of solubilisation buffer, then applied to a column and 
centrifuged for 1 min at 16,100 g. The column was washed once with 600 µl wash buffer. 
Finally, the DNA was eluted in appropriate volume (25-50 µl) of ultra pure H20.  
 
 
2.2.4 Topo-cloning reaction  
 
The TOPO-cloning reaction was performed according to a modified TOPO TA Cloning® 
protocol from Invitrogen GmbH. Therefore, 4 µl of fresh PCR-product was solved in ultra 
pure H2O with 1 µl of salt solution and 0.5 µl of pCR®2.1-TOPO® vector solution to a final 
volume of 6 µl. This mixture was incubated for 5 min at room temperature and then mixed 
with E. coli TOP10 cells for transformation using the heat shock protocol in section 2.2.6. 
The suspension containing the bacteria was spread out on LB-agar plates containing 50 
µg/ml carbenicillin and 50 µl of 40 mg/ml X-gal dimethlyformamide-solution used for the 
blue/white screening. The plates were incubated overnight at 37°C. White colonies were 
picked and prepared according to section 2.2.7. 
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2.2.5 Digestion, ligation and precipitation of plasmid DNA 
 
Amounts of 50-200 ng DNA (analytical digest) or 1-2 µg DNA (preparative digest) were 
digested in 1x specific enzyme buffer with 5-10 U or 20-50 U of enzyme in a 10 or 50 µl 
reactions according to manufacturer’s manual.  The digested DNA was visualised by agarose 
gel electrophoresis.  
The ligation reaction was carried out either at room temperature for 3 h or overnight at 14°C 
in 1x ligation buffer. Exact 200 U T4 DNA ligase was added to a final volume of 10 µl. The 
molar vector to insert ratio was approximately 1 to 3. In some cases, an in-gel ligation was 
performed by excising a low melt agarose gel slice containing the DNA and melting it at 
65°C, it was then kept at 37°C. The volume was estimated by measuring the weight of the 
melted gel pieces. The concentration of DNA was estimated from the gel before the DNA 
was cut out. Mixing of liquid gel, buffer and enzyme occurred at 37°C, before incubating at 
14°C overnight or at room temperature for 3 h. Buffers, enzymes and molar ratios were used 
as described above. 
If necessary, the plasmid-DNA was purified using the NaCl-EtOH method. In brief, NaCl to 
a final concentration of 0.5 M and 2-3 volumes of 100% absolute EtOH were mixed with the 
DNA solution and placed at -20°C for at least 1 h. After centrifuging at 16,100 g at 4°C for 
20 min, the DNA-pellet was washed twice in 1 ml of 70% EtOH, air dried and resuspended 
in an appropriate volume of ultra pure H20. 
 
 
2.2.6 Transformation of competent E. coli cells 
 
E. coli TOP10 (Invitrogen GmbH) were cultured at 37°C in LB medium using 50 µg/ml 
carbenicillin as an ampicillin analogue for pcDNA3.1 based vectors or 50 µg/ml kanamycin 
for pEGFP based vectors. For long term storage, the cell pellet was resuspended in LB 
medium containing ampicillin or kanamycin with 25-50% (v/v) glycerol and kept at -70°C. 
The cells were transformed according to the manufacturer’s protocol. Briefly, 50 µl aliquots 
were thawed on ice, 50-200 µg of DNA solved in water volumes of 2-5 µl was added and 
carefully mixed and then incubated on ice for 15-30 min. After a heat shock incubation at 
42°C for 20-30 s, bacteria were returned to ice for 5 min and then grown in pre-warmed LB 
medium with shaking (200 rpm) at 37°C for 60 min. 100 µl of bacteria suspension was 
spread out on a petri dish containing LB medium with 1.5% (w/v) agar and appropriate 
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antibiotics and then incubated at 37°C overnight. Single colonies were picked and inoculated 
in 5 ml LB medium containing appropriate antibiotics overnight with shaking (200 rpm) at 
37°C. Following this, a small and later a large-scale isolation of plasmid DNA was 
performed. 
 
LB medium 
 10 mg/ml NaCl  
 10 mg/ml  Tryptone 
 5 mg/ml  Yeast extract (ICN Biochemical, Inc., Cleveland, USA) 
 
 
2.2.7 Small and large scale isolation of plasmid DNA 
 
The Macherey-Nagel NucleoSpin® Plasmid Kit was used to isolate plasmid DNA from 
bacteria in a small volume according to the manufacturer’s instructions. In brief, overnight 
cultures were centrifuged at 16,100 g. The cell pellet was then resuspended in 250 µl 
resuspending buffer, lysed in 250 µl lysis buffer and neutralised with 300 µl neutralisation 
buffer. After centrifugation at 16,100 g for 10 min the supernatant was applied to a column 
and centrifuged for 1 min at 16,100 g. After washing the column with 500 µl wash buffer 
once, the DNA was eluted in appropriate volume of ultra pure H20.   
To prepare larger amounts of highly pure plasmid DNA the Macherey-Nagel NucleoBond® 
PC 500 plasmid kit was used according to the manufacturer’s instructions. Briefly, 200 ml of 
an overnight culture were centrifuged at 4°C for 15 min at 6,000 g in a standard 
ultracentrifuge (AvantiTM J-25, Beckmann Coulter GmbH, Krefeld, Germany) using a JLA-
10.500 rotor. The cell pellet was resuspended in 12 ml resuspending buffer, lysed in 12 ml 
lysis buffer and neutralized with 12 ml of neutralisation buffer. After removing bacterial cell 
debris by filtering, the DNA containing solution was applied to an AX 500 column. After 
washing it twice with 18 ml washing buffer the plasmid DNA was eluted from the column 
with 15 ml elution buffer. The plasmid DNA was precipitated with 11 ml of 100% 
isopropanol and centrifuged for 30 min at 11,000 g in a JS-13.1 rotor. After decanting the 
supernatant the DNA pellet was resuspended in 500 µl ultra pure H20. If necessary, the DNA 
was precipitated with the NaCl-ethanol method. Briefly, the DNA was precipitated with a 
final of 0.5 M NaCL and two volumes of EtOH for 30 min at -20°C. The solution was then 
centrifuged at 16,100 g for 10 min at 4°C before washed with 70% EtOH and again 
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centrifuged. The DNA pellet was air dried and dissolved in an appropriate volume of ultra 
pure H20. 
Plasmid concentrations were estimated by measuring the absorbance at 260 nm in a standard 
spectrometer (Nano-Drop NP-1000). The purity was estimated by reading the absorbance at 
280 nm and calculating the ratio of OD260 to OD280. 
 
 
2.2.8 DNA sequencing 
 
The sequencing reactions were performed by MWG Biotech AG using primers binding the 
T7 promotor and BGH reserve priming sites within the pcDNA3.1(+) vector or primers 
binding the M13 forward or reverse priming sites within the pCR®2.1-TOPO® vector. 
 
 
2.3 Cell culture 
 
2.3.1 Cell lines 
 
Cells were maintained in exponential growth in 10 cm culture dishes, TS-25 or TS-75 culture 
flasks as a monolayer in a humidified 10% CO2 atmosphere incubator (APT.lineTM CB 150 
or 250, BINDER GmbH, Tuttlingen, Germany ) at 37°C. The human embryonic kidney 293 
cell lines (HEK293, # ACC 305 & HEK293T, # ACC 635, DSMZ, Braunschweig, Germany) 
were grown in complete DMEM, whereas the human urinary bladder carcinoma cell line 
(ECV304, # ACC 310) was grown in complete M199 medium. Stably transfected cell lines 
were additionally maintained in medium containing 1 mg/ml G418 sulfate (Calbiochem, San 
Diego, USA). All HEK293 and ECV304 based cells lines were passaged by washing once 
with Dulbecco's PBS (without Ca & Mg) and using trypsin/EDTA for 5 min for cell 
detachment. For long term storage, cell pellets were resuspended in freezing medium, frozen 
for 24-48 h at -80°C and then stored in liquid nitrogen. 
 
Freezing medium 
 40% (v/v)  complete DMEM or M199 
 10% (v/v)  DMSO 
 50% (v/v)  Fetal bovine serum "GOLD" 
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Complete DMEM 
 10% (v/v)  Fetal bovine serum "GOLD" 
 100 U/ml  Penicillin 
 100 µg/ml  Streptomycin  
 in   DMEM high Glucose (with L-Glutamine) 
 
Complete M199 
 10% (v/v) Fetal bovine serum "GOLD" 
 100 U/ml  Penicillin 
 100 µg/ml  Streptomycin  
 in   Medium 199 with Earle's Salts (with L-Glutamine) 
 
 
2.3.2 Isolation of peripheral blood mononuclear cells and neutrophils 
 
Human peripheral blood was supplied by healthy male and female donors. If not otherwise 
stated in the text, the total isolation procedure was performed at room temperature. 2 ml of 
3.1% (w/v) sodiumcitrate-2 hydrate (Eifelfango®, J. Graf Metternich GmbH & Co. KG, Bad 
Neuenahr-Ahrweiler, Germany) were immediately added to approximately 23 ml blood and 
then mixed with equal amounts of Dulbecco's PBS (without Ca & Mg). 50 ml of this solution 
were carefully placed onto 30 ml of 1.077 g/ml human pancoll (PAN-Biotech GmbH, 
Aidenbach, Germany) in two 50 ml tubes and centrifuged for 35 min at 400 g without 
breaking force resulting in fractions of erythrocytes, neutrophils, pancoll solution, peripheral 
blood mononuclear cells (PBMC) and blood plasma.  
After removal of the blood plasma, the PBMC fraction was collected, washed twice with 20-
30 ml Dulbecco's PBS (without Ca & Mg) using 400 g for 5 min before finally being 
resuspended in 0.2% (w/v) BSA in serum-free RPMI medium to a concentration of 2x 106 
cells / ml.  
The neutrophil fraction was also collected after further removal of the pancoll solution. 
Contaminating erythrocytes were lysed by adding 5-10 ml erythrocyte-lysisbuffer. The cells 
were washed with 20-30 ml of Dulbecco's PBS using 400 g for 5 min until the cell pellet 
remain clear (erythrocyte free). The neutrophils (2x 106 / ml) were then resuspended in 0.2% 
(w/v) BSA in serum-free RPMI 1640 medium (with L-glutamine). 
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Erythrocyte-lysisbuffer 
 155 mM  NH4Cl 
 1 mM   KHCO3
 137 µM  EDTA 
 
 
2.3.3 Transient transfection of mammalian cell lines 
 
Lipofectamine™ 2000 transfection reagent (Invitrogen GmbH) was used to transfect cells 
according to the manufacturer’s instructions. Briefly, cells were grown in complete medium 
overnight until they reached 50-70% confluence. Transfection reagent was carefully diluted 
in 100 µl serum-free medium and incubated for 5 min at room temperature before it was 
dropped onto the DNA and incubated for 20 min. The mixture was added to the cells, which 
prior received serum-free medium. After 24 h, the medium was changed to complete medium 
and cells were grown for further 24 h. The ratio of transfection reagent to DNA was 3:1.    
 
 
2.3.4 Generation of stable cell lines 
 
Cells were transiently transfected for 48 h according to section 2.3.2 before the medium was 
replaced by complete medium containing 1 mg/ml G418 sulfate for the selection of 
transfected cells. The medium and selection reagent was changed every two days for 2-3 
weeks. After this period the cells were rinsed off with trypsin/EDTA, transferred to a 96 well 
plate in a dilution of one cell per well and grown for 1-2 weeks. A pre-screening of the cells 
for expression of the transfected proteins was performed by ELISA and the final selection of 
the cell clones was done by using flow cytometry according to sections 2.4.2 and 2.3.6. 
 
 
2.3.5 Generation of lentiviral derived shRNA HEK293 knockdown system 
 
For generating specific transcriptional knockdown for human ADAM10 and ADAM17, a 
lentiviral derived expression systems was applied using short-hairpin RNA (shRNA) 
sequences for ADAM10 and ADAM17 according to the Laboratory of Virology and 
Genetics (Ecole Polytechnique Fédérale de Lausanne, Prof. Didier Trono) with the help of 
the AG Ludwig lab member F.M. Hess. The shRNA targeting sequences for ADAM10 (5’-
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GACATTTCAACCTACGAAT-3’) were annealing at position 650-668 of the ADAM10 
mRNA, whereas the targeting sequences for ADAM17 (5’-AGGAAAGCCCTGTACAGTA-
3’) were annealing at position 2061-2079 of the ADAM17 mRNA. The following sequence 
5’-GCGTCACATCAATTGCCGT-3’ served as scrambled control. To generate the shRNA a 
9-nucleotide noncomplementary spacer sequence (TTCAAGAGA) was used for all 
sequences. The shRNA sequences, supplied from MWG Biotech (Ebersberg, Germany) were 
inserted into the lentiviral expression vector pLVTHM upon MluI and ClaI restriction 
enzymes digest and  screened using EcoRI and ClaI and subsequently verified by sequencing.   
To produce virus with the target vector pLVTHM containing the shRNA sequences 
HEK293T cells were seeded onto a 10 cm cell culture dish for one day (1.5x 106 per plate) 
and then transfected using the jetPEI transfection reagent (PEQLAB Biotechnologie GmbH, 
Erlangen, Germany). Thereby, 10 µl of jetPEITM reagent was used with 250 µl of 150 mM 
Chlorure Sodium Solution and mixed with 2.5 µg of target vector pLVTHM, 0.9 µg of the 
pMD2.G envelope vector and 1.6 µg of psPAX2 packaging vector and incubated for 15 min. 
The mixture was applied to the HEK293T cells. The medium was changed after 4 h, 1 day 
and 2 days before the supernatant was harvested on day 3 by centrifugation for 5 min at 500 
g. To remove the cell debris subsequent filtering of the supernatant through a 0.22 µm filter 
was applied. Subsequently hexadimethrine bromide (Sigma-Aldrich GmbH) was added to a 
final of 8 µg/ml.  
The HEK293 cells stable expressing the mCX3CL1 were then seeded onto a 6-well plate (1x 
105 / well / 2ml). The following day they were transduced with the 1 ml of corresponding 
supernatant containing the viruses. HEK293 cells were re-infected after 48 h and left 
untreated for further 48 h. Surface expression of ADAM10 was then analysed by flow 
cytometry. 
 
 
2.3.6 Detection of the surface expression by flow cytometry  
 
Cells were harvested using trypsin/EDTA or accutase. Unless otherwise stated the total 
protocol was performed at 4°C. 5x105 cells were stained for 30 min in 50 µl flow cytometry 
buffer using 1 µg/ml of the first antibody of interest or of the isotype control. A human 
CX3CL1-Fc construct was also used for detection as a control of the surface expression. 
Human CX3CL1 binds the mouse receptor CX3CR1 and can then be itself detected by 
antibodies against the Fc-tail. In this case, conditioned medium of HEK293 cells expressing 
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the CX3CL1-Fc construct was used as a positive control and the medium of untransfected 
HEK293 cells as negative control. Both media were diluted 1 to 10 in flow cytometry buffer 
and incubated for 20 min with the respective antibody. Cells were then washed once using 
500 µl flow cytometry buffer and centrifuged at 1,000 g for 5 min. The appropriate 
secondary antibody was then applied according to manufacturer’s instructions for further 30 
min. Cells were washed 3 times and fixed in PBS with 1% (w/v) PFA. The analysis of the 
stained cells was performed in either a Guava EasyCyte mini flow cytometer (Millipore, 
Billerica, USA) or a FACSCalibur flow cytometer (BD Biosciences). Data were analysed 
using the WinMDI software (WinMDI version 2.9, Copyright© 1993-2000 Joseph Trotter) or 
the FlowJo software (FlowJo flow cytometry analysis software version 7.2.5, Tree Star, 
Inc.1997-2009) and either shown by dot plot or histogram.  
 
Flow cytometry buffer 
 0.2% (w/v)  BSA 
 137 mM  NaCl 
 2.7 mM KCl 
 10 mM  Na2HPO4
 2 mM   KH2PO4 
 
Antibodies and Sera 
hCX3CL1-Fc 10x conditioned medium of HEK293 cells expressing 
the CX3CL1-Fc construct for 24 h, diluted 1 to 10 
 
control-Fc 10x conditioned medium of untransfected HEK293 
cells for 24 h, diluted 1 to 10  
 
α-mCX3CL1 goat IgG anti-mouse CX3CL1 antibody, #AF472, 
R&D Systems GmbH, Germany, used at 1 µg/ml 
 
goat IgG  normal goat IgG isotope antibody, #AB-108-C, R&D 
Systems GmbH, Germany , used at 1 µg/ml 
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α-hA10 mouse IgG2B anti-human ADAM10 ectodomain 
antibody, #MAB1427, R&D Systems GmbH, 
Germany, used at 1 µg/ml 
 
mouse IgG2B mouse IgG2B isotype antibody, #MAB004, R&D 
Systems GmbH, Germany, used at 1 µg/ml 
 
α-hCX3CR1-PE R-phycoerythrin(PE)-conjugated rat IgG2b anti-
human CX3CR1 antibody, #D070-5, MBL 
International, Woburn, USA, used at 1 µg/ml 
 
rat IgG2b-PE R-phycoerythrin(PE)-conjugated rat IgG2b kappa 
isotype antibody, #ab18537, Abcam Inc., Cambridge, 
USA, used at 1 µg/ml 
 
α-goat FITC Fluoresceinisothiocyanat(FITC)-conjugated rabbit 
anti-goat IgG antibody, #F7367, Sigma-Aldrich 
GmbH, diluted 1 to 200 
 
α-hFc PE  R-phycoerythrin(PE)-conjugated goat F(ab') 2 
Fragments anti-human IgG Fc γ-fragment , #109-116-
170, Jackson ImmunoResearch Laboratories Europe 
Ltd., Suffolk, UK, used at 2 µg/ml 
   
α-mouse APC Allophycocyanin-conjugated goat anti-mouse IgG1-3 
antibody, #115-135-164, Jackson ImmunoResearch 
Laboratories Europe Ltd., Suffolk, UK, used at 5 
µg/ml 
 
 
2.3.7 Immunofluorescence 
 
15 x 15 mm cover slips were coated with 0.01% (w/v) poly-L-lysine in ultra pure H20 for 15 
min at room temperature, washed twice with ultra pure H20 and air dried for approximately 
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60 min before being transferred into 12-well cell culture plates.  The wt HEK293 cells were 
seeded using 5x 104 cells per 500 µl. Liposomal transfection was carried out after cells 
reached 50% confluence. All following steps were carried out at room temperature. Cells 
were washed twice in PBS and fixed in 4% (w/v) paraformaldehyde-PBS for 15 min. Free 
aldehyde groups were quenched with 50 mM NH4Cl in PBS for 10 min. Cells were 
permeabilised in 1% (v/v) Triton X in PBS for 4 min and blocked in 5% FCS (v/v) in PBS 
for 30 min. The cells were then stained with 4µg/ml of primary antibody diluted in 5% FCS 
(v/v) in PBS for 30 min, washed three times with PBS and incubated with the secondary 
antibody diluted in PBS with 2.5% FCS (v/v) for a further 30 min. If more then one primary 
antibody was used, cells were stained sequentially. Cells were then washed four times in 
PBS. After this, cells were washed again with PBS for 15 min. Finally, they were briefly 
washed in MilliQ® H20, before being mounted on microscope slides in mowiol. For storage 
at 4°C for more than one week, the edges were covered with nail polish. The cell proteins 
were visualised using the LSM 510 confocal laser scanning microscope (Carl Zeiss AG, 
Oberkochen, Germany) at the Institute for Biochemistry and Molecular Biology (Laboratory 
of Cytokine Signal Transduction, Prof. Dr. Gerhard Mueller-Newen). 
 
Antibodies 
α-mCX3CL1 goat IgG anti-mouse CX3CL1 antibody, #AF472, 
R&D Systems GmbH, used at 5 µg/ml 
 
α-goat 488 Alexa Fluor® 488-conjugated donkey anti-goat IgG 
antibody, # A-11055, Invitrogen GmbH, used at 10 
µg/ml 
 
 
2.3.8 Adhesion assay 
 
This static one cell adhesion assay was performed in a Nunc MaxiSorbTM flat-bottom 96-well 
plate (eBioscience, Ltd., Hatfield, UK). The plate was coated with the rat α-mCX3CL1 
antibody diluted in PBS at room temperature. After 24 h free antibodies were removed and 
the plate was washed twice with PBS. After blocking in 2% BSA/PBS for 2 h, the plate was 
washed again two times with PBS. HEK293 cells were harvested using trypsin/EDTA and 
placed onto the antibody coated plate with a concentration of 1-2x 105 cells per well. Cells 
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were sedimented onto the plates by centrifugation with 1,000 g for 1 min and incubated for 5 
min in a humidified 10% CO2 atmosphere incubator at 37°C.  
Unbound cells were washed away with pre-warmed PBS followed by four additional 
washing steps. The number of the cells bound prior to the washing and after the various wash 
steps was estimated using the method for detection of the endogenous β-glucoronidase 
according to section 2.3.3. To correlate β-glucoronidase activity with cell numbers a standard 
curve starting with 1x 106 cells per well in eight 1 to 2 dilution steps was performed.  
 
Antibody 
rat α-mCX3CL1 rat IgG2A anti-mouse CX3CL1 antibody, 
#MAB571, R&D Systems GmbH, used at 4 µg/ml 
 
 
2.3.9 Transmigration assay 
 
ECV304 cells (2-3x 104 cells / well) and HEK293 cells (3-4x 104 cells / well) were seeded 
onto 24-well polycarbonate-membrane transwell-filters (Vitaris AG, Baar, Germany) with a 
pore size of 5 µm for 2 days until they reached 100% confluence. Cells were carefully 
washed once with 100 µl of Dulbecco's PBS before 2x 105 fresh isolated PBMCs or 
neutrophils were added to the upper chamber of the Transwell system. The lower chamber 
contained 500 µl of serum-free RPMI medium with 0.2% BSA containing different 
chemotactic stimuli like 2.5 nM human IL-8, 6 nM human CCL2 (MCP-1) or 12 nm human 
CX3CL1. Neutrophils were allowed to transmigrate towards the lower chamber for 30-45 
min, whereas PBMCs were allowed to transmigrate for 2-3 h. The medium of the lower 
chambers containing the transmigrated cells was then divided in equal volumes of 250 µl. 
The cells were then centrifuged at 1,000 g for 5 min, the supernatant was removed and the 
cell pellets were resuspended in 100 µl Dulbecco's PBS. By measuring the endogenous β-
glucoronidase activity (see section 2.4.3) the number of transmigrated cells in this 100 µl was 
estimated and extrapolated to 500 µl. To be able to correlate endogenous β-glucoronidase 
activity to cell numbers a standard curve starting at 2x 106 cells per well in escalating steps of 
1 to 2 dilution was performed. 
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2.4 Protein chemistry 
 
2.4.1 Preparation of conditioned cell medium and cell lysates 
 
To obtain conditioned cell medium containing soluble proteins, serum-free medium was 
added to HEK293 cell for 24 h, removed and mixed with complete protease inhibitor cocktail 
(Roche Diagnostics GmbH, Mannheim, Germany) according to the instructions. The cell 
medium was then centrifuged at 16,100 g for at least 10 min before the supernatant was 
placed into a fresh tube. If used for Western blotting, the supernatant was then concentrated 
5-10 times using the Vivaspin 500 centrifugal filters (Sartorius Stedim Biotech S.A., 
Aubagne Cedex, France) with a molecular weight cut off of 3, 5 or 10 kDa.   
For the preparation of the cell lysates, HEK293 cells were harvested from the plates by 
rinsing them off with ice cold PBS, ECV304 cells were rinsed off by using trypsin/EDTA. 
Cells were centrifuged at 1,000 g for 5 min at 4°C. Subsequently the cell pellet was lysed in 
lysis buffer by incubation on ice for 10-15 min. Cellular debris and supernatant containing 
proteins were separated by centrifugation for 10 min. The supernatant was transferred to a 
fresh tube and stored at -20°C.  
Protein amounts were estimated by using the DC protein assay (Bio-Rad Laboratories 
GmbH, Munich, Germany) according to the manufacturer’s instructions. The absorbance of 
the samples was measured in a GENios microplate reader at 562 nm. 
 
Lysis buffer 
137 mM  NaCl 
2.7 mM  KCl 
10 mM  Na2HPO4
2 mM   KH2PO4 
1% (v/v) Triton X-100 
1x   complete protease inhibitor cocktail 
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2.4.2 Enzyme-linked Immuno-sorbant Assay (ELISA) 
 
The mouse CX3CL1 ELISA was performed using the DuoSet ELISA Kit (R&D Systems 
GmbH) according to the manufacturer’s instructions. The human CX3CL1 and the human 
CCL5 (RANTES) ELISA was performed using antibodies as  indicated below. 
All following steps were performed at room temperature. Samples, standards and antibody 
were diluted in 2% BSA/PBS-N-05 unless stated in the text. In brief, 2-5 µg/ml of capture 
antibody was coated to a Nunc MaxiSorbTM flat-bottom 96-well plate overnight in PBS. The 
plate was blocked in 2% BSA/PBS-N-05 for 1-2 h before the samples and corresponding 
controls in different dilutions were incubated on the plate also for 1-2 h. Plates were washed 
three times with PBS-N. Following this, 200-400 ng/ml of detection antibody was added to 
the plate for another 1-2 h. Before the Streptavidin-HRP was applied for 30 min, the plates 
were washed again three times with PBS-N-05. Substrate solution was added to the plate for 
5-15 min and the reaction was stopped with the same volumes of 2 N H2SO4. The optical 
density was measured in a GENios microplate reader at 450 nm and corrected by subtraction 
of the optical density at 550 nm.  
 
PBS-N-05 
 0.05% (v/v)  Tween 20 
 137 mM  NaCl 
 2.7 mM KCl 
 10 mM  Na2HPO4
 2 mM   KH2PO4 
 
Antibodies 
mFKN ELISA DuoSet ELISA Development Kit (# DY472) 
 
α-hCX3CL1 mouse IgG1 anti-human CX3CL1 capture antibody, 
#MAB365, R&D Systems GmbH, used at 3 µg/ml 
 
α-hCX3CL1-biotin  biotinylated goat IgG anti-human CX3CL1 detection 
antibody, #BAF365 R&D Systems GmbH, used at 
300 ng/ml 
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α-hRANTES mouse IgG1 anti-human CCL5 capture antibody, 
#MAB678, R&D Systems GmbH, used at 4 µg/ml 
 
α-hRANTES-biotin biotinylated goat IgG anti-human CCL5 detection 
antibody, #BAF278, R&D Systems GmbH, used at 
400 ng/ml 
 
 
 
2.4.3 The β-glucoronidase assay 
 
Cell numbers were indirectly measured using p-nitropheny-β-D-glucoronide as a substrate, 
which is cleaved by the β-glucuronidase located in the lysosomes of the cells. In brief, cells 
were lysed in 100 µl of 0.1% Triton in PBS for 5 min, 100 µl substrate solution containing p-
nitropheny-β-D-glucoronide was added and incubated overnight at room temperature. The 
reaction was stopped by addition of 100 µl 0.4 M glycin, pH 10.3. The extinction of the cell 
lysates was measured in a GENios microplate reader at 405 nm. To be able to correlate 
endogenous β-glucoronidase activity to cell numbers a standard curve was generated by 
serial dilutions (1 to 2) of a cell suspension, previously defined by counting in a 
haemocytometer. 
 
Substrate solution 
0.1 M   Na-acetate, pH 4 
10 µM  p-nitropheny-β-D-glucoronid (Calbiochem, USA) 
 
 
2.4.4 Shedding assay 
 
Shedding assays were performed in culture plates with 5x 105 cells per 6-well or 1x 105 cells 
per 24-well. Cells were either transfected transiently according to section 2.4.3 for 48 h or 
stably expressed different proteins of interest. Cells were seeded for 24 h and then serum 
starved in presence or absence of different stimuli or inhibitors for additionally 24 h medium. 
Conditioned medium (750 µl) and cell lysates (200 µl) were prepared as described in section 
2.4.1 and subjected to ELISA as indicated in section 2.4.2. Subsequently, the measured 
concentration of CX3CL1 in the medium and cell lysate was further calculated by dividing 
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through 9.24, which represents the molecular mass of the chemokine domain of CX3CL1 (84 
amino acids = 9,240 Da), resulting in the molar concentration of CX3CL1 [pmol/ml]. This 
was then multiplied with 0.75 (medium) and 0.2 (lysat), which finally resulted in the molar 
amount of CX3CL1 [pmol] in the whole medium and cell lysate sample. Following this, the 
release rate [%] of various CX3CL1 constructs was calculated as the ratio of the amount of 
soluble CX3CL1 in the medium and the amount of soluble CX3CL1 in the medium plus the 
cell-associated CX3CL1 in the cell lysates.       
 
 
2.4.5 Tandem protein purification 
 
HEK293 cells were transiently transfected with the pcDNA3.1 vector containing a human 
CX3CL1 C-terminal tagged with a 2z und a histidin domain according to section 2.4.3. The 
cell lysate of one 10 cm culture dish was harvested after 48 h using the 1 ml lysis buffer 
(section 2.3.1).  
100 µl of IgG-sepharoseTM 6 fast flow (Amersham, GE Healthcare, Munich, Germany) was 
washed three times with TST-buffer by resuspension and centrifugation with 0.5 g for 1 min 
at 4°C and finally resuspended in 2 ml TST-buffer. 2 ml of IgG-sepharose solution and 1ml 
of cell lysate were incubated under agitation for 1-2 h at 4°C. Subsequently, the proteins 
bound to the IgG-sepharose were washed three times with TST-buffer by resuspension and 
centrifugation with 0.5 g for 1 min at 4°C. Proteins were eluted in 300 µl 0.5 M acetic acid 
(pH 3.4). The solution was then neutralised with 150 µl 1 M Tris (pH 11) and the buffer was 
finally changed to 1 ml PBS-N-05 (see section 2.4.2) using the illustra NAP™-10 columns 
(GE Healthcare) according to manufacturer’s protocol.   
In a second step, 100 µl of Ni-NTA agarose (QIAGEN GmbH, Hilden, Germany) was 
washed three times with equilibration buffer using 0.5 g for 1 min at 4°C and finally 
resuspended in 1 ml equilibration buffer. 1 ml of Ni-NTA solution and 1ml of the protein 
solution from the first purification step were again incubated under agitation for 1-2 h at 4°C. 
The Ni-NTA agarose was then washed two times with equilibration buffer and two times 
with Ni-NTA wash buffer before the protein was eluted with 300 µl of Ni-NTA elution 
buffer. By the use of illustra NAP™-10 columns the buffer was again exchanged to 1 ml 
equilibration buffer according to manufacturer’s protocol. The eluted protein was then 10 
times concentrated using the Vivaspin 500 centrifugal filters with a molecular weight cut off 
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of 10 kDa. Some fractions of the purification procedure were then subjected to SDS-PAGE 
and Western blotting. 
 
TST buffer 
50 mM  Tris HCl, pH 7,6 
150 mM  NaCl 
0.05 % (v/v)  Tween 20 
 
Equilibration buffer 
 0.05 % (v/v)  Tween 20 
 in   PBS 
 
Ni-NTA wash buffer 
20 mM  Imidazol  
 0.05 % (v/v)  Tween 20 
 in   PBS 
 
Ni-NTA elution buffer 
250 mM  Imidazol  
 0.05% (v/v)  Tween 20  
 in   PBS 
 
 
2.4.6 Deglycosylation 
 
Tandem purified human CX3CL1-2zHis protein or unpurified human cell bound CX3CL1 
protein (transiently expressed for 48hrs in HEK293 cells) were subjected to deglycosylation. 
In order to get complete O-deglycosylation, the endo-α-N-acetylgalactosaminidase 
(Calbiochem) and the α2-3,6,8,9-neuraminidase (Calbiochen) were used together. The endo-
α-N-acetylgalactosaminidase cleaves only unsubstituted Galβ1,3GalNAc disaccharides 
attached to serine or threonine residues, whereas the α2-3,6,8,9-neuraminidase hydrolyses all 
non-reducing terminal sialic acid residues. Purified cell lysate (13 µl), deglycosylation buffer 
(4 µl), endo-α-N-acetylgalactosaminidase (2 µl) and α2-3,6,8,9-neuraminidase (1 µl) were 
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mixed and incubated for 2 h at 37°C. Afterwards the proteins/lysates were analysed in 
comparison to the unglycosylated proteins/lysates by Western blotting.  
.  
Deglycosylation buffer (pH 5) 
250 mM  NaH2PO4
250 mM  Na2HPO4   
 
 
2.4.7 SDS-PAGE 
 
Sodiumdocecylsulfate-polyacrylamid-gelelectrophoresis (SDS-PAGE) was carried out on 
12.5% separating gels with a 5% stacking gels unless otherwise stated in the text. The gels 
were electrophoresed in a Mini-PROTEAN® 3 cell system (Bio-Rad Laboratories) containing 
SDS running buffer at 50-75 V (Power pac 200, Bio-Rad Laboratories) for 60-90 min at 
room temperature. Samples were loaded in the presence of 5x sample buffer together with 
PageRuler™ prestained protein ladder (Fermentas GmbH) according to Laemmli150.  
 
Separating gel 
 2.5 ml   1.5 M Tris-Base pH 8.8 
 3.3-5 ml Rotiphorese® Gel 30 (37.5:1)  
 0.1% (w/v) SDS 
 0.1% (w/v) APS 
 10 µl   TEMED  
 add   10 ml (MilliQ® H20) 
 
Stacking gel 
 1.25 ml   0.5 M Tris-Base pH 6.8 
 0.85 ml  Rotiphorese® Gel 30 (37.5:1) 
 0.05% (w/v)  SDS 
 0.05% (w/v) APS 
 5 µl   TEMED  
 add   5 ml (MilliQ® H20) 
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SDS running buffer 
 25 mM  Tris-Base 
 200 mM  Glycine 
 0.1% (w/v)  SDS 
 
5x sample buffer 
 250 mM Tris-Base 
 10% (w/v) SDS 
 0.1% (w/v) Bromphenol blue 
 50% (v/v) Glycerol 
 2% (v/v) β-mercaptoethanol 
 
 
2.4.8 Western blotting 
 
Proteins separated by SDS-PAGE were electrophoretically transferred to a PDVF blotting 
membrane (GE Healthcare) using the TransBlot® semi dry system (Bio-Rad Laboratories) in 
transfer buffer at 1 mA per cm2 membrane for 1.5 h at room temperature. All following steps 
were performed at room temperature. The membrane was blocked by shaking in blocking 
solution (10% BSA/PBS-N-1 or 5% milk powder/PBS-N-1). The membrane was then 
incubated with the first antibody in blocking solution for 45-60 min at room temperature and 
washed three times for 5 min with PBS-N-1. The protein/first antibody complex was then 
detected with the appropriate secondary antibody coupled to the horse radish peroxidase 
(HRP) for another 45-60 min. Afterwards the membrane was washed four times for 5 min 
with PBS-N-1. The equal volumes of LumigenTM TMA-6 Solution A and B (GE Healthcare) 
were placed onto the membrane for 45-60 s. The intensity of the chemo-luminescent HRP 
reaction was measured for 1-120 s with the LAS-3000 Gel-analyser (FUJIFILM Europe 
GmbH, Duesseldorf, Germany).      
 
Transfer buffer 
 25 mM  Tris-Base 
 192 mM  Glycine  
 10% (v/v) Methanol 
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PBS-N-1 
 0.1% (v/v)  Tween 20 
 137 mM  NaCl 
 2.7 mM  KCl 
 10 mM  Na2HPO4
 2 mM   KH2PO4 
 
Antibodies 
α-hCX3CL1 rabbit anti-human CX3CL1 antibody, #500-P98, 
PeproTech GmbH, used at 250 ng/ml 
 
α-mCD4 rat IgG2B anti-mouse CD4 antibody, #MAB5541, 
R&D Systems GmbH, used at 1µg/ml 
 
α-rabbit HRP  Horse radish peroxidase-conjugated goat F(ab') 2 
fragments anti-rabbit IgG, #111-036-003, Jackson 
ImmunoResearch Laboratories Europe, Ltd., used at 
32 ng/ml 
α-rat HRP  Horse radish peroxidase-conjugated goat F(ab') 2 
fragments anti-rat IgG, #112-036-003, Jackson 
ImmunoResearch Laboratories Europe, Ltd., used at 
32 ng/ml 
 
 
2.5 Data illustrations and statistical analysis 
 
The graphs display the result as mean ± SD (standard deviation) of three independent 
experiments, if not indicated otherwise.  
All data were generally Box-Cox transformed prior the statistical analysis using the JMP 
software (JMP, Version 7, SAS Institute Inc., Cary, NC, 1989-2007) to reduce the possibility 
of the data to not contain equal variances (homoscedasticity). Since data shown in percent are 
believed to be not Gauss distributed, these data were also AcrSine transformed using the 
Excel software (Microsoft® Office Excel 2003, Microsoft Corporation, Seattle, WA, 1985-
2003) to achieve Gaussian distribution. The data were subsequently analyzed using t-test and 
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one- or two-way analysis of variance (ANOVA) using the GraphPadPrism software 
(GraphPad Prism 5.02, GraphPad Software, San Diego, CA, 1992-2009). In case of one-
factor analysis the paired t-test was used for single comparison, whereas for one-factor 
multiple comparison the one-way ANOVA was used. Two-way ANOVA was performed for 
two-factor multiple comparison analysis. As post-hoc tests after the one- or two-way 
ANOVA the Bonferroni or the Dunnett tests were used. The Bonferroni test was used to 
compare all data against all other data, whereas the Dunnett test was used to compare all data 
against the control. The data were then considered significantly different at probability values 
smaller 0.05 (0.01, 0.001), marked with * (**, ***). In the figures only those comparisons 
with interest to the main hypotheses were indicated. 
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3 3   RESULTS 
 
 
3.1 Structural characterisation of mouse CX3CL1 
 
Several reports have described ADAM mediated shedding of human CX3CL1. However, 
shedding of mouse CX3CL1 remains to be analysed in detail. In the present study the 
domains within CX3CL1 involved in shedding by ADAM10 were analysed. For this purpose, 
shedding of mouse CX3CL1 was analysed and compared to human CX3CL1. Subsequently, 
the cleavage region for human CX3CL1 was defined in more detail. Finally, the molecular 
determinats for the ADAM10 mediated shedding within the whole mouse CX3CL1 were 
analysed.  
 
 
3.1.1 Shedding of mouse CX3CL1 
 
Shedding of human CX3CL1 is well characterised, whereas shedding of mouse CX3CL1 
remain to be investigated. Here, shedding of the mouse CX3CL1 mediated by human 
ADAM10 and ADAM17 was analysed and compared to the human variant. Therefore, an 
expression system for mouse CX3CL1 was generated. The vector map of the mCX3CL1 
expression vector (mCX3CL1_3.1+) and the sequence of mouse CX3CL1 are shown in the 
supplement section (Sup.-Fig. 1a, b). The mCX3CL1_3.1+ vector was generated by 
amplifying the CX3CL1 gene from the pORF-mFractalkine vector (supplied by InvivoGen, 
San Diego, USA) using the 5mFKNEcoRI_fo and 3mFKNXhoI_re primers at an annealing 
temperature of 55°C. The gene-sequence was ligated into the pCR2.1 Topo vector, verified 
by sequencing and then subcloned into the pcDNA3.1+ vector using EcoRI and XhoI 
restriction enzymes. 
The domain structures of human and mouse CX3CL1 are schematically presented in Fig. 3-1 
[A]. To compare the expression, human and mouse CX3CL1 were transiently expressed in 
HEK293 cells. The conditioned medium and cell lysates of both CX3CL1 forms were then 
subjected to SDS-PAGE followed by Western blotting using an antibody against human and 
mouse CX3CL1 (Fig. 3-1 [B]). It was found that soluble forms of hCX3CL1 were released 
into the conditioned medium and migrated at a molecular weight of approximately 70 kDa. 
The soluble forms of mCX3CL1 seemed to migrate slightly lower than 70 kDa. Two 
predominant cell-associated molecules were detected in the cell lysates of hCX3CL1 and 
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mCX3CL1 transfected HEK293 cells. For hCX3CL1 they were detected at around 55 and 90 
kDa, respectively and for mCX3CL1 at around 60 and 90 kDa.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-1: Shedding of hCX3CL1 and mCX3CL1 into the medium of HEK293 cells 
[A] Schematic presentation of the domain structures of human CX3CL1 (X3CL1_HUMAN 
(accession #P78423)) and mouse CX3CL1 (X3CL1_MOUSE (#O35188)) indicated by the 
number of the first amino acid residue of each domain. The light gray bars represent the 
signal peptides, the green bars the chemokine domains, the dark grey bars the mucin-like 
stalk, the white shaped bars the transmembrane domain and the blue bars the cytoplasmic tail 
containing the potential tyrosine phosphorylation motif. The two potential cleavage sites 
within the mucin-like stalk, which are represented through the di-argine motif (R-R) and one 
of the potentially o-glycosylated threonine residues (T). [B] Conditioned medium (M) and 
cell lysates (L) of human (hCX3CL1) and mouse CX3CL1 (mCX3CL1), expressed in 
HEK293 cells, were subjected to SDS-PAGE followed by Western blotting using the rabbit 
α-hCX3CL1 antibody and the α-rabbit HRP antibody for the detection. The pcDNA3.1+ 
vector (pcDNA) served as control. 
 
 
The Western blot analysis showed that soluble forms of human and the mouse CX3CL1 with 
a size of approximately 70 kDa were released into the medium. Since the cell surface 
expressed form has a size of approximately 90 kDa141, this release was most likely caused by 
proteolysis/shedding from the cell surface. Already published data using specific inhibitors 
for ADAM10 (A10) and ADAM10/17 (A10/17) and ADAM10-defiencient embryonic 
fibroblasts suggested that this constitutive release of the human CX3CL1 is due to 
A
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ADAM10-mediated shedding146, whereas the PMA-induced release of human CX3CL1 is 
mediated by ADAM17141.  
The human and mouse CX3CL1 forms were transiently expressed in HEK293 cells to 
analyse the involvement of ADAM10 and ADAM17 in the release of mouse CX3CL1. 
Transfected cells were incubated in the absence or presence of the specific inhibitors A10 
and A10/17 and analysed for soluble forms found in the conditioned medium by ELISA (Fig. 
3-2). The dual-specific A10/17 inhibitor was already reported to have an IC50 against 
ADAM17 of 8.0 nM and an IC50 of 11.5 nM against ADAM10, whereas the specific A10 
inhibitor was reported to have an IC50 against ADAM10 of 5.3 nM146. In the present study it 
was demonstrated that soluble forms of mouse CX3CL1 can be found in the conditioned 
medium, as they can be for human CX3CL1. The release of both human and mouse forms 
was inhibited by the A10 and A10/17 inhibitors, however, in both cases the A10/17 inhibitor 
seemed to be the more effective. Application of both inhibitors reduced the release of human 
CX3CL1 up to approximately 75%, whereas the combined use of A10 and A10/17 inhibited 
the release of mouse CX3CL1 up to approximately 66%. Since application of both A10 and 
A10/17 inhibitors led to the highest reduction of soluble CX3CL1 released into the medium, 
they were used in combination in further experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-2: Analysis of the conditioned media of hCX3CL1 and mCX3CL1 tranfected 
HEK293 cells 
Human [A] and mouse [B] CX3CL1 were expressed in HEK293 cells and analysed for 
shedding in the presence of the inhibitors A10 and A10/17 (10 µM) by ELISA for human 
and mouse CX3CL1. DMSO served as control. ELISA data given in the diagram correlate 
with the CX3CL1 molecules, which were released into the medium. One well contained 1x 
105 cells. The means and standard deviations (SD) of three independent experiments are 
shown. Statistical analysis was performed using one-way ANOVA followed by Bonferroni 
post-hoc test. The p-values indicated as *, **, *** were smaller than 0.05, 0.01, 0,001. 
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3.1.2 Structural determinants for shedding of mouse CX3CL1 
 
3.1.2.1 Cleavage sites for human CX3CL1 
 
The di-argine (R-R) motif was predicted to represent the cleavage site of human CX3CL1. 
Mouse and human CX3CL1 share great sequence homology. Thus, the R-R motif can also be 
found in the mouse CX3CL1. But furthermore, it was necessary to narrow down the cleavage 
site in more detail and also check whether also more than one cleavage site within CX3CL1 
is used by ADAM10. 
For this purpose advantage was taken of the already generated 2zHis-tagged human CX3CL1 
molecule. It contained the human CX3CL1 molecule fused to Xa-restriction site (4 amino 
acids), a 2z-tag (138 amino acids) and a His tag (6 amino acids). By the use of this construct, 
C-terminal fragments (CTFs) located within the cell membranes can be purified using protein 
A and Ni-NTA. The construct was expressed in HEK293 cells and tandem purified from the 
cell lysates according to section 2.4.5. The proteins were purified by sequential binding of 
the IgG-bound Sepharose to the 2z-tag and subsequent binding of Ni-NTA-bound Agarose to 
a six histidine containing tag. All fractions of the tandem purification were subjected to SDS-
PAGE followed by Western blotting (Fig. 3-3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-3: Tandem purification of hCX3CL1 
The human CX3CL1-2zHis vector was transfected into HEK293 cells and after 48 h the cell 
lysate was harvested and subjected to protein batch purification using IgG-Sepharose (IgG), 
NAP10 purification colums (NAP) and Ni-NTA-Agarose (Ni-NTA). The cell lysate (L) and 
selected fractions, like binding (B), washing (W) and elution (E), were analysed by SDS 
PAGE  followed by Western blotting using the rabbit α-hCX3CL1 and the α-rabbit HRP 
antibodies. The arrows indicate the C-terminal fragments CTF1-3. 
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For the detection of the C-terminal fragments an antibody was used, which binds the 2z-tag 
of the molecule allowing the detection of all fragments with an intact C-terminus. Western 
blot analysis indicated that the 2zHis-tagged human CX3CL1 was purified from the cell 
lysate already by the first IgG-Sepharose purification step and even more specific by the 
following Ni-NTA purification step. Additionally, after the tandem purification three CTFs 
were attached via the 2zHis tag. The CTF1 migrated at approximately 18 kDA, whereas the 
CTF2 and the CTF3 had a size of approximately 22 and 24 kDa. 
 
The mucin-like stalk of CX3CL1 contains 26 potential O-glycosylations at serine and 
threonine residues52. Since potential O-glycosylations are also found in the membrane 
proximal region, the CTFs might also carry O-glycosylations.  
To address this question the purified 2zHis human CX3CL1 and untagged human CX3CL1 
were O–deglycosylated using the endo-α-N-acetylgalactosaminidase in combination with the 
α2-3,6,8,9-neuraminidase according to section 2.4.6. The protein was then subjected to 15% 
SDS-PAGE and Western blotting (Fig. 3-4). Three CTFs with the sizes of approximately 23, 
24 and 25 kDa were found. However, upon O-deglycosylation only the two smaller CTFs at 
23 and 24 kDa were detected. The experiments indicated that only the CTF3 rises from 
different glycosylation. This suggested that maximal two cleavage sites exist, represented by 
the CTF1 and CTF2. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-4: Deglycosylation of  hCX3CL1 
The purified protein CX3CL1-2zHis (2zHis) was untreated (-) and treated (+) using Endo-α-
N-acetylgalactosaminidase and the α2-3,6,8,9-Neuraminidase. Untagged human CX3CL1 
(wt) served as control. The samples were then analysed by 15% SDS-PAGE followed by 
Western blotting using the rabbit α-hCX3CL1 and the α-rabbit HRP antibodies. The arrows 
indicate three C-terminal-fragments (CTF) with a size of approximately 23, 24 and 25kDa.  
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3.1.2.2 Substitution of the cleavage region 
 
The data above demonstrated that the cleavage/shedding of human CX3CL1 takes place at 
the extra-cellular part of the protein proximal to the membrane and involves more than one 
cleavage site. The release of mouse CX3CL1 appears to be ADAM10- and ADAM17-
dependent as indicated by the profiles of specific inhibitors A10 and A10/17. However, the 
region containing the cleavage sites of CX3CL1 not necessarily represents the determinants 
for the recognition of CX3CL1 through ADAM10 or ADAM17. Therefore, mutants for 
studying the structural determinants for CX3CL1 shedding were generated. These 
investigations not only addressed the membrane proximal cleavage region within CX3CL1, 
but also analysed the chemokine domain, the transmembrane domain and the intracellular C-
terminal part (Fig. 3-5). Analogous domains within mouse CX3CL1 were replaced by 
corresponding structures of related molecules or completely deleted and in a next step the 
amounts of released versus cell-associated variants were analysed by ELISA.  
 
 
 
 
 
 
 
 
 
 
                
Fig. 3-5: Potential target structures to analyse mCX3CL1 shedding 
 
 
Since CX3CL1 appears to be cleaved proximal to the membrane at two potential cleavage 
sites this region seemed to be a promising target to define the structural determinants for the 
shedding process by ADAM10 and ADAM17.  
For this purpose, the following chimeras and variants of mCX3CL1 were generated. First, the 
mCX3CL1/CD4 chimera was generated containing the extracellular Ig-like C2-type 3 
domain (57 amino acids) and the extracellular juxtamembrane domain (21 amino acids) of 
mouse CD4. The two domains replaced the amino acids 262 to 339 of mouse CX3CL1, 
which are the first 78 amino acids in the extracellular mucin-like stalk orientated from the 
membrane. Secondly, a mCX3CL1 poly-L variant containing a 50 amino acid poly-(glycine-
serine) residue (poly-L) replacing the corresponding part of mCX3CL1 from amino acids 290 
CX3CCX3C CX3CCX3C
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to 339 was also generated. The mCX3CL1/CD4 and the mCX3CL1 poly-L variant 
expression vectors and the sequence of the chimetic genes are shown in the supplement 
section (Sup.-Fig. 2a, b, c). To generate the vectors, the cDNAs for the Ig-like C2-type 3 
domain of mouse CD4 and the poly-(glycine-serine) residue were synthesized (Genscript, 
USA) and provided within a pUC57 expression vector. They were then subcloned into the 
mCX3CL1_3.1+ using Eco81I and XhoI restriction enzymes and verified by sequencing. 
Furthermore a mCX3CL1 variant (mCX3CL1 del) with a deletion of 50 amino acids from 
290 to 339 was also generated. The vector map and the sequence are shown in the 
supplement section (Sup.-Fig. 3a, b). For the generation of the mCX3CL1 del variant, which 
was derived from the mCX3CL1 poly-L chimera, the BamHI restriction enzyme was used. 
The structure of all generated chimeras and variants is schematically shown in Fig. 3-6 [A].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-6: Substitution and 
deletion of the membrane 
proximal part of mCX3CL1 
by an Ig-like domain of 
mCD4 and a poly-(glycine-
serine) linker 
[A] Schematic structure of the 
mCX3CL1 chimeras/variants 
with a substitution or deletion 
in the membrane proximal 
part of mCX3CL1 are shown. 
The indicated mCX3CL1 
chimeras/variants were 
expressed in HEK293 cells 
and analysed for shedding by 
ELISA. ELISA data in the 
diagram were shown as the 
released CX3CL1 in the 
medium [B], the released and 
cell-associated CX3CL1 in the 
medium and the cell lysate [C] 
and the release rate [D] 
representing the ratio between 
the amount of soluble 
CX3CL1 released in the 
medium and the total amount 
of all CX3CL1 molecules 
found in the medium and cell 
lysates. The means and 
standard deviations (SD) of 
three independent experiments 
are shown. Statistical analysis 
was performed using one-way 
ANOVA. 
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The mCX3CL1, the mCX3CL1/CD4 chimera, the mCX3CL1 poly-L and the mCX3CL1 del 
variants were expressed in HEK293 cells and analysed for the presence of soluble and cell 
associated mouse CX3CL1 by ELISA. As indicated in Fig. 3-6 [B-D] the amount of soluble 
CX3CL1 in the medium and total amount of CX3CL1 in medium and cell lysate varied 
among the constructs.  
To compare the release of different variants, a release rate was defined, representing the ratio 
(in percent) between the amount of soluble CX3CL1 released in the medium and the total 
amount of all CX3CL1 molecules found in the medium and cell lysates (for details see 
section 2.4.4). This release rate appears to better represent the release of CX3CL1, since it 
relates the released forms in medium to the total amount of released and cell-associated 
forms. In this experiment the wt form of mouse CX3CL1 showed a release rate of 50%. The 
release rates of the mCX3CL1 poly-L and the mCX3CL1 del variants were slightly 
increased. Only the mCX3CL1/CD4 chimera showed a slight reduction in the release rate 
compared to mCX3CL1. 
 
 
3.1.2.3 Substitution of the N-terminal region 
 
Unexpectedly, the release of mouse CX3CL1 was significantly affected neither by the 
substitution of the membrane proximal region by that of a mouse CD4 domain, nor by an 
artificial poly glycine-serine linker nor by a total deletion. It was therefore speculated that 
other determinants might influence the ADAM10 and ADAM17 shedding of CX3CL1. Thus, 
the involvement of the chemokine domain in CX3CL1 release was analysed. CCL5 plays an 
active role in the recruitment of the leukocytes into the inflammatory sites. It was reported to 
be involved in the monocyte arrest151. Since it has a similar function as CX3CL1, it was 
decided to change the chemokine domain of mouse CX3CL1 to that of human CCL5.  
The CCL5/mCX3CL1 chimera was generated by substitution of the chemokine domain of 
mouse CX3CL1 (76 amino acids) by that of human CCL5 (68 amino acids) including the 
signal peptide motif (23 amino acids) of CCL5. The CCL5/mCX3CL1 expression vector 
(RANmCX3CL1_3.1+) and the sequence of the gene are also shown in the supplement 
section (Sup.-Fig. 4a, b). The vector was generated by amplification of CCL5 from a CCL5-
pCDNA3.1+ vector construct (kindly provided by Priv.-Doz. Dr. Rory Koenen, IMCAR, 
RWTH Aachen) using the 5hRANEcoRI_fo and 3hRANAgeI_re primers at an annealing 
temperature of 60°C. The upper part of the mucin-like stalk of CX3CL1 was amplified from 
the mCX3CL1_3.1+ vector using the 5mFKNAgeI_fo and 3mFKNPflAge_re primers also at 
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an annealing temperature of 60°C. Both PCR-products were subcloned into the pCR2.1 Topo 
before the sequence for the upper part of the mCX3CL1 stalk region was ligated behind the 
CCL5 sequence using the AgeI restriction site. The orientation of the gene sequences was 
verfied by sequencing before the total sequences was back ligated into mCX3CL1_3.1+ 
vector using EcoRI and PflMI restriction sites. The schematic structure of this construct is 
shown in Fig. 3-7 [A]. The CCL5/mCX3CL1 chimera was then transiently expressed in 
HEK293 cells in the absence or presence of both specific inhibitors for ADAM10 (A10) and 
ADAM10/17 (A10/17). Subsequently medium and cell lysates were subjected to the ELISA 
for the determination of the release rate (Fig. 3-7 [B]).  
Since the changing of the CX3C-chemokine domain also destroyed the epitope for the mouse 
CX3CL1 ELISA, an ELISA for CCL5 had to be used. This ELISA revealed that the release 
rate of the CCL5/mCX3CL1 chimera was increased up to nearly 80%, whereas the release 
rate of the wt mCX3CL1 shown in the previous experiment was only 50%. The A10 and 
A10/17 inhibitors, however, could not reduce the release of the CCL5/mCX3CL1 chimera to 
a significant extent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-7: Substitution of the chemokine domain of mCX3CL1 by the chemokine CCL5 
[A] The schematic structure of the CCL5/mCX3CL1 is shown. [B] HEK293 cells were 
transiently transfected with the CCL5/mCX3CL1_3.1+ vector. Conditioned medium and cell 
lysate was analysed for the release and inhibition by A10 and A10/17 using the ELISA for 
CCL5. ELISA data presented in the diagram are shown as release rate. The means and 
standard deviations (SD) of three independent experiments are shown. Statistical analysis was 
performed using paired two-tailed t-test. 
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3.1.2.4 Substitution and removal of the transmembrane and the C-terminal region 
 
Obviously none of the introduced mutations led to a pronounced reduction of CX3CL1 
release.  Hence, the focus was now changed to the C-terminal and the transmembrane regions 
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of mCX3CL1. These two regions in combination with the membrane proximal region of 
mouse CX3CL1 were replaced by that of the mouse CD4 analogous regions and analysed for 
the release behaviour. 
In the mCX3CL1/CD4 fusion chimera amino acids 262 to 395 of mouse CX3CL1 were 
replaced by the C-terminal part of mouse CD4 including the cytoplasmic tail, the 
transmembrane region and the Ig-like C2-type 3 domain. The mCX3CL1/CD4 fusion vector 
(mCX3CL1/CD4fusion_3.1+) and the gene-sequence are shown in the supplement section 
(Sup.-Fig. 5a, b). Before generating the fusion vector, the mouse CD4 vector (mCD4_3.1+) 
was constructed. The vector map and the sequence are shown in Sup.-Fig. 6a, b. Therefore, 
the mouse CD4 (mCD4; CD4_MOUSE (#P06332)) gene provided from RZPD (ImaGenes, 
Germany) was amplified using 5mCD4EcoRI_fo and 3mCD4XhoI_re primers at an 
annealing temperature of 55°C. It was subcloned into the pCR2.1 Topo vector, then verified 
by sequencing and subsequently again subcloned into the pcDNA3.1+ vector upon EcoRI 
and XhoI restriction enzyme digest. Thereafter, the upper part of the mCX3CL1/CD4 
chimera including parts of the Ig-like C2-type 3 domain was amplified using the 
5mFKNEcoRI_fo and 3mFKNCD4Bam_re primers also at an annealing temperature of 55°C 
and cloned into the pCR2.1 Topo vector. Sequencing reactions and subcloning into the 
mCD4_3.1+ vector via the BamHI restriction sites were performed afterwards, resulting in 
the generation of the mCX3CL1/CD4 fusion vector. The schematic structures of the 
mCX3CL1/CD4 fusion chimera, the mCX3CL1/CD4 chimera and mCX3CL1 are shown in 
Fig. 3-8 [A]. The indicated chimeras were expressed in HEK293 cells. Subsequently, 
conditioned medium and cell lysates were analysed for released and cell-associated variants 
using SDS-PAGE and Western blotting (Fig. 3-8 [B]).  
Soluble forms of mCX3CL1/CD4 and mCX3CL1/CD4 fusion chimeras were released into 
the conditioned medium and migrated like mCX3CL1 at a molecular weight of 
approximately 70 kDa, probably even slightly lower. Interestingly, two molecules of 
approximately 55 and 60 kDA were seen in the medium of the mCX3CL1/CD4 chimera and 
one molecule of approximately 65 kDa in the medium of the mCX3CL1/CD4 fusion 
chimera. The analysis of the cell lysates revealed different molecules for all variants. Two 
molecules at approximately 60 and 90 kDa were found in the cell lysate of HEK293 cells 
expressing mCX3CL1. In the cell lysate of HEK293 cells expressing the CX3CL1/CD4 
chimera also two proteins were detectable. One was detected at approximately 90 kDa, 
whereas the second one was detected slightly lower than 60 kDa. This smaller protein was, 
however, remarkably stronger expressed than the corresponding mCX3CL1 protein. In the 
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HEK293 cell lysate of the mCX3CL1/CD4 fusion chimera two main molecules at 
approximately 50 and 80 kDa were found.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-8: Substitution of the membrane proximal part or the transmembrane and 
intracellular domains of mCX3CL1 by that of mCD4 
[A] The mCX3CL1 variant and both mCX3CL1/CD4 and mCX3CL1/CD4 fusion chimeras 
are schematically shown. [B] Conditioned medium (M) and cell lysates (L) of HEK293 cells 
expressing the indicated chimeras were subjected to SDS-PAGE followed by Western 
blotting using the rabbit α-hCX3CL1 and α-rabbit HRP antibodies. The arrows indicate the 
soluble forms of the wt mCX3CL1 and the mCX3CL1 chimeras, which were released into the 
medium.  
 
 
The Western blot analysis also showed that soluble forms were released into the conditioned 
medium of the mCX3CL1 chimera transfected cells, most likely by proteolysis/shedding of 
the mature forms from the surface. To clarify whether ADAM10 and ADAM17 are involved 
in the shedding of the mCX3CL1/CD4 fusion chimera, this chimera was treated with the 
inhibitor A10 and A10/17 and further analysed by ELISA. For this purpose the 
mCX3CL1/CD4 and the mCX3CL1/CD4 fusion chimera were transiently expressed in 
HEK293 cells. The transfected cells were incubated in the absence or presence of the specific 
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inhibitors A10 and A10/17. The conditioned medium and cell lysates were subsequently 
analysed by ELISA for mouse CX3CL1 (Fig. 3-9). The mCX3CL1 served as control. 
A reduction of the release rate was again observed for the mCX3CL1/CD4 chimera 
compared to the wt mCX3CL1, whereas for the mCX3CL1/CD4 fusion protein a slight 
increase in the release rate could be seen. The release of all variants was diminished by the 
A10 and A10/17 inhibitors to a similar degree of 25%.  
 
 
 
 
 
 
 
 
 
 
Fig. 3-9: Analysis of the release of mCX3CL1/CD4 and mCX3CL1/CD4 fusion 
The indicated mCX3CL1/CD4 and mCX3CL1/CD4 fusion chimeras were expressed in 
HEK293 cells and analysed for the release in the absence or presence of the inhibitors for 
A10 and A10/17 by ELISA. ELISA data given in the diagram are shown as release rate. The 
means and standard deviations (SD) of three independent experiments are shown. Statistical 
analysis was performed using two-way ANOVA followed by Bonferroni post-hoc test. The p-
values indicated as *, ** were smaller than 0.05, 0.01. 
 
 
Shedding of CD4 has not yet been reported, in particular not by ADAM10- and ADAM17-
mediated mechanisms. The unexpected observations that the mCX3CL1/CD4 and the 
mCX3CL1/CD4 fusion chimeras were still shed, led also to the investigation of the potential 
shedding of mouse CD4 itself. The mCD4_3.1+ expression vector map and sequence is 
shown in the supplement section and the generation was already described above. The 
schematic structure of the mouse CD4 molecule is shown in Fig. 3-10 [A]. The mCD4_3.1+ 
was also transiently transfected in HEK293 cells, after 48 h the medium and the cell lysates 
were subjected to SDS-PAGE and Western blotting (Fig. 3-10 [B]).  
As a result, two soluble forms of mCD4 were released into the conditioned medium with a 
size of approximately 55 and 60kDa. The full size molecule present in the cell lysate 
migrated at approximately at 60 kDa. This indicated that also mouse CD4 is shed to some 
degree from the cell surface.  
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Fig. 3-10: Release of mCD4 
[A] Mouse CD4 was amplified and subcloned into the  pcDNA3.1+ vector. [B] HEK293 cells 
were transiently transfected with the mCD4_3.1+ vector and analysed for the release into the 
conditioned medium by Western blotting using the rat α-mCD4 antibody and the α-rat HRP 
antibody for detection.  
 
 
The results described above indicated that the replacement of the membrane proximal and the 
C-terminal parts by that of analogous mouse CD4 regions does not lead to a reduction in the 
ADAM10- or ADAM17-mediated release. The mCX3CL1/CD4 and the mCX3CL1/CD4 
fusion showed no significant reduction in shedding, Even shedding of the total mouse CD4 
molecule was observed, questioning whether other molecules can be used as replacement 
molecules in order to reduce shedding by ADAM10 or ADAM17.  
Other studies reported that C-terminal interactions are involved in the processes of ADAM12 
mediated shedding of the epidermal growth factor (EGF) Receptor Ligand152. A more 
interesting target to mediate shedding was therefore seen in the C-terminal cytoplasmic part 
of CX3CL1 containing a potential SH2-binding domain motif, which could be responsible 
for potential interactions. 
The C-terminal cytoplasmic tails of the mCX3CL1 and mCX3CL1/CD4 chimera were 
therefore truncated and then investigated for shedding via ADAM10 and ADAM17. The 
mCX3CL1 trunc and mCX3CL1/CD4 trunc chimeras were generated by truncation of the 
cytoplasmic tail of the CX3CL1 molecules, integrating a stop codon five amino acids 
proximal to the membrane on the intracellular C-terminal site at the amino acid 362 of the 
mouse CX3CL1 molecule. This seemed to be enough to anchor the protein within the 
membrane on the one hand and on the other hand to destroy all possibilities for CX3CL1 to 
bind ADAM10 or ADAM17 at the cytosolic part. Both expression vectors for the mCX3CL1 
trunc (mCX3CL1 trunc_3.1+) and mCX3CL/CD4 trunc (mCX3CL1/CD4 trunc_3.1+) and 
the gene-sequences are shown in the supplement section (Sup.-Fig. 7a, b & Sup.-Fig. 8a, b). 
To generate the vectors, the partial genes from both mCX3CL1_3.1+ and 
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mCX3CL1/CD4_3.1+ vectors were amplified using 5mFKNPflI_fo and 3mFKNStopI_re 
primers at an annealing temperature of 55°C. Both PCR-products were subcloned into the 
pCR2.1 Topo vector and then verified by sequencing. They were afterwards back subcloned 
into the mCX3CL1_3.1+ and mCX3CL1/CD4_3.1+ vectors upon PflMI and XhoI restriction 
enzyme digest. The schematic structures of both truncated mCX3CL1 and mCX3CL1/CD4 
chimeras and of the untruncated mCX3CL1 form are shown in Fig. 3-11 [A]. The indicated 
truncated mCX3CL1 variant and the truncated mCX3CL1/CD4 chimera were also transiently 
expressed in HEK293 cells and again analysed for the release into the conditioned medium 
by SDS-PAGE and Western blotting (Fig. 3-11 [B]).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-11: Truncation of the cytoplasmic tail of mCX3CL1 and mCX3CL1/CD4 
[A] The intracellular C-terminal cytoplamic tail of mouse CX3CL (mCX3CL1 trunc) and of 
mCX3CL1/CD4 (mCX3CL1/CD4 trunc) was truncated at the amino acids 362 of mouse 
CX3CL1. [B] Conditioned medium (M) and cell lysates (L) of the indicated truncated 
variants/chimeras and the untruncated mCX3CL1, expressed in HEK293 cells, were 
subjected to SDS-PAGE followed by Western blotting using the rabbit α-hCX3CL1 antibody 
and α-rabbit HRP detection antibody. 
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weight of approximately 70 kDa. The mCX3CL1/CD4 trunc showed a faint additional 
molecule in the medium at approximately 65 kDa. The analysis of the cell lysate showed that 
both truncated chimeras were expressed as two molecules of approximately 55 and 80 kDa, 
whereas the untruncated mCX3CL1 was expressed as two molecules of approximately 60 
and 90 kDa, as it was already shown above. 
 
The Western blotting revealed that the truncated mCX3CL1 variant and the truncated 
mCX3CL1/CD4 chimera were expressed in the cell lysate as approximately 80 kDa mature 
proteins. Proteins of approximately 70 kDa were found in the conditioned medium, 
indicating that shedding also occurred for the truncated variants/chimeras. It was then 
important to know if and how the shedding of these truncated chimeras is affected by 
ADAM10- and ADAM17-mediated mechanisms. The mCX3CL1 trunc and the 
mCX3CL1/CD4 trunc were therefore again transiently expressed in HEK293 cells and 
incubated in the absence or presence of specific A10 and A10/17 inhibitors. They were 
afterwards analysed for soluble forms found in the conditioned medium and cell associated 
forms in the cell lysate by ELISA (Fig. 3-12). The wt mCX3CL1 served as control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-12: Release of mCX3CL1 trunc and mCX3CL1/CD4 trunc 
The truncated mCX3CL1 and mCX3CL1/CD4 chimeras were expressed in HEK293 cells, 
then analysed for shedding in the presence of the inhibitors A10 and A10/17 and compared to 
the untruncated mCX3CL1. ELISA data shown in the diagram are presented as release rate. 
The means and standard deviations (SD) of three independent experiments are shown. 
Statistical analysis was performed using two-way ANOVA followed by Bonferroni post-hoc 
test. The p-values indicated as **, *** were smaller than 0.01, 0,001. 
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reduced by an inhibition of ADAM10 and ADAM17. Shedding of the truncated 
mCX3CL1/CD4 chimera was also reduced to a degree of 40%. This reduction was, however, 
not as strong as the reduction observed for the truncated mCX3CL1 form. Inhibition of 
ADAM10 and ADAM17 reduced the release rate to a degree of 25% for all analysed 
variants/chimeras. The level was about the same as that for mCX3CL1. This indicates that 
the level of ADAM10 and ADAM17 independent shedding is the same for all variants. 
All previous results on the N-terminal, the cleavage region and the C-terminal associated 
variants/chimeras revealed that the C-terminal truncation of mCX3CL1 caused the most 
pronounced reduction in the release of mCX3CL1 into the conditioned medium. Next, the 
influence of the C-terminal truncation of mCX3CL1 was investigated in a model of induced 
shedding by inomycin. Treatment with ionomycin leads to increased intracellular Ca++ and to 
activation of ADAM proteins. In case of CX3CL1 this ionomycin-induced shedding is 
exclusively mediated by ADAM10-activity146.  
HEK293 cells were therefore transiently transfected with the mCX3CL1 and the truncated 
mCX3CL1 vectors for 72 h. The A10 inhibitor was then added for 10 min before an 
incubation with ionomycin for 20 min. After this incubation period conditioned medium and 
cells lysates were harvested and analysed by ELISA (Fig. 3-13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-13: Ionomycin-induced release of the truncated mCX3CL1 and mCX3CL1/CD4  
chimeras 
The truncated mouse CX3CL1 chimera (mCX3CL1 trunc) and mCX3CL1 (mCX3CL1) 
(mCX3CL1/CD4 trunc) were transfected in HEK293 cells. After 72 h cells were treated with 
or  without 10 µM of specific ADAM10 inhibitor for 10 min and afterwards for 20 min with 
1 µM ionomycin or left totally untreated at standard cell culture conditions. Conditioned 
medium and cell lysat were harvested and analysed for the presence of mouse CX3CL1 by 
ELISA. Data shown in are shown as release rate. The means and standard deviations (SD) of 
three independent experiments are shown. Statistical analysis was performed using two-way 
ANOVA followed by Bonferroni post-hoc test. The p-values indicated as *, ** were smaller 
than 0.05, 0.01. 
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It was found that the release rate of mCX3CL1 after 20 min of ionomycin treatment was 
significantly increased, which was not the case for the truncated mCX3CL1. Ionomycin-
induced release of mCX3CL1 and truncated mCX3CL1 was suppressed by the inhibitor A10. 
This experiment also indicates that the release rates were as expected again reduced for the 
truncated variants of mCX3CL1 in comparison to the wt mCX3CL1.    
The experiments above demonstrated that truncation of mCX3CL1 results in the strongest 
reduction in constitutive and ionomycin-induced release. In a next step it was analysed 
whether the reduced release of the truncated mCX3CL1 variant could be potentially 
influenced by a different cellular distribution compared to wt mCX3CL1. Therefore, 
HEK293 cells were transiently transfected with the truncated and wt mCX3CL1 vectors, as 
described in section 2.3.6 (Fig. 3-14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-14: Confocal analysis of mCX3CL1 and mCX3CL1 trunc 
The mCX3CL1 [A, C] and the truncated mCX3CL1 [B, D] variants were transfected in 
HEK293 cells and analysed for the cellular distribution using confocal microscopy. Cells 
were stained using the goat α-mCX3CL1 antibody in combination with the α-goat 488 
antibody for the detection. Representative pictures of two independent experiments are 
shown. Arrows indicate mCX3CL1 variants within the cell surface membrane (yellow), the 
perinuclear golgi-like structures (red) and the vesicle-like structures (white). 
A B
C D
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The microscopic analysis of transfected and stained cells showed that both truncated and full-
lenght variants were expressed on the cell surface, as expected. Interestingly, both variants 
were also found within the cells in perinuclear golgi-like structures. However, the truncated 
mCX3CL1 variant showed a rather equal distribution within the cell, whereas the wt 
mCX3CL1 seemed to be expressed also in distinct vesicle-like structures within the cell.   
 
 
3.1.3 Generation and characterisation of HEK293 cells stably expressing wt and 
truncated mCX3CL1 
 
The results above showed that the release rate of truncated mCX3CL1 was reduced 
compared to mCXCL1, which was also seen for the ionomycin-induced release rates. 
Microscopic analysis indicated that although they were both expressed on the cell surface 
and showed perinuclear staining in golgi-like structures, the truncated mCX3CL1 variant 
showed no additional staining of vesicle-like structures. All these results led to the hypothesis 
that the release of these mCX3CL1 variants may not be necessarily due to different shedding. 
Effects of different protein expression and trafficking have to be considered as well. A 
uniform surface expression of both variants could help to understand the influence of the C-
terminal tail of CX3CL1 on ADAM mediated shedding in more detail. 
Therefore, HEK293 cells were transiently transfected with the mCX3CL1, the truncated 
mCX3CL1 variant and the truncated mCX3CL1/CD4 chimera for 48 h and subsequently 
analysed for surface expression by flow cytometry (Fig. 3-15).   
All three analysed mCX3CL1 variants seemed to display similar surface expression profiles. 
But the specific analysis of cells expressing higher levels of mCX3CL1 (> 97% of isotype 
control; gated M1-M3) indicated a higher expression degree (median) for the wt mCX3CL1 
variant as for the truncated mCX3CL1 and mCX3CL1/CD4 chimera. 
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Fig. 3-15: Flow cytometric analysis of the truncated mCX3CL1 variants and 
mCX3CL1/CD4 chimera 
[A] The previously generated truncated variants/chimeras were transfected in HEK293 cells 
and subsequently analysed for surface expression by flow cytometry using the goat α-
mCX3CL1 antibody. The goat IgG antibody served as an isotype control and the α-goat FITC 
antibody was used for the detection. The wt mCX3CL1 served as control. A representative 
figure of three measurements is shown. [B] The mouse CX3CL1 wt (wt), the mouse CX3CL1 
trunc (trunc) and the mouse CX3CL1/CD4 trunc (CD4 trunc) were gated (M1-3) for 
approximately 3% of isotype control.  The median of the gated cells of three flow cytometric 
measurements is shown as mean and as standard deviation (SD). Statistical analysis was 
performed using one-way ANOVA followed by Dunnett post-hoc test. The p-values indicated 
as ** were smaller than 0.01. 
 
 
In order to get a high and uniform expression of all CX3CL1 variants, HEK293 cells were 
then stably transfected with mCX3CL1 and truncated mCX3CL1. Transfected HEK293 cells 
were selected by mCX3CL1 geneticin (G418) treatment for 3-4 weeks. The cells were pre-
screened by ELISA for high concentrations of shed mouse CX3CL1 in the medium and 
subsequently analysed by flow cytometry for similar surface expression profiles. According 
to their similar surface expression profiles the following two cell clones were chosen for 
further analysis: Clone #12 stably expressing mCX3CL1 and clone #16 stably expressing the 
truncated mCX3CL1. Both surface expression profiles are shown in Fig. 3-16. 
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Fig. 3-16: Flow cytometric analysis of stable mCX3CL1- and mCX3CL1 trunc-HEK293 
cells  
[A] Hek293 cells stably expressing mouse CX3CL1 (mCX3CL1-HEK293) and mouse 
CX3CL1 trunc (mCX3CL1 trunc-HEK293) were generated according to section 2.3.4 and 
subsequently analysed for CX3CL1 expression by flow cytometry using the goat α-
mCX3CL1 antibody as indicated before. A representative figure of three independent 
experiments of the indicated cell lines is shown in [B].  
 
 
After screening the HEK293 cell clones for similar surface expression, they were analysed 
for the release of soluble mCX3CL1 in the absence or presence of the inhibitors for A10 and 
A10/17. Conditioned medium and cell lysates of the mCX3CL1-HEK293 cells and 
mCX3CL1 trunc-HEK293 cells were analysed for soluble and cell-associated forms of 
mouse CX3CL1 by ELISA (Fig. 3-17).  
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Fig. 3-17: Release of soluble mCX3CL1 in stable mCX3CL1-HEK293 and mCX3CL1 
trunc-HEK293 cells using the A10 and A10/17 inhibitors 
The previously generated HEK293 cells stably expressing mouse CX3CL1 (mCX3CL1) and 
truncated mouse CX3CL1 (mCX3CL1 trunc) were analysed for shedding in the absence and 
presence of the specific inhibitors A10 and A10/17. ELISA data shown in the diagram are 
presented as released CX3CL1 in the medium [A], as released and cell-associated CX3CL1 
in the medium and the cell lysate [B] and as release rate [C] representing the ratio between 
the amount of soluble CX3CL1 released in the medium and the total amount of all CX3CL1 
molecules found in the medium and cell lysates (for details see section 2.4.4). The means and 
standard deviations (SD) of three independent experiments, performed as duplicates or 
triplicates, are shown. Statistical analysis was performed using two-way ANOVA followed 
by Bonferroni post-hoc test. The p-values indicated as *, **, *** were smaller than 0.05, 
0.01, 0,001. 
 
 
Interestingly, the amount of the shed CX3CL1 from the truncated variant was more than 
twice as high as from the wt mCX3CL1. Release of mCX3CL1 trunc and mCX3CL1 were 
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similar inhibited by ADAM10. Notably, the cell-associated of truncated mCX3CL1 were 
higher expressed than the wt mCX3CL1. Therefore, the release rate for the truncated variant 
of mCX3CL1 was reduced compared to the wt (untruncated) variant. In the presence of the 
inhibitors, the release rates of the truncated and un-truncated variants were both reduced to 
about 25%.  
 
In the experiments above HEK293 cells were generated expressing both mCX3CL1 variants 
to a similar surface. Although even more soluble forms of truncated mCX3CL1 were found 
in the medium, the A10 inhibitor showed similar inhibition ratios (approximately 75%) for 
shedding of truncated and wt mCX3CL1. Therefore, a similar role for ADAM10 for the 
release of both variants has to be considered. To analyse this effect more specifically 
lentiviral shRNA knockdown of ADAM10 and ADAM17 was used in the stable HEK293 
cells. 
The lentiviral derived expression systems using shRNA sequences for ADAM10 and 
ADAM17 knockdown were used (for details see section 2.3.5). Briefly, the shRNA 
sequences were inserted into the lentiviral expression vector pLVTHM upon MluI and ClaI 
restriction enzyme digest. They were then screened using EcoRI and ClaI and subsequently 
verified by sequencing.  Afterwards the HEK293 cells stably expressing mCX3CL1 and 
mCX3CL1 trunc were transduced with the psPAX2 packaging vector, the pMD2.G envelope 
vector and the pLVTHM vector containing the target sequences for ADAM10, ADAM17 and 
control knockdown. Subsequently, the lentivirally transduced GFP expressing HEK293 cells 
were first screened for GFP expression by flow cytometry. GFP positive cells were further 
screened for the ADAM10 expression using the α-hA10 antibody (Fig. 3-18 [A]). The 
generated HEK293 cell lines were then analysed for the release of soluble mCX3CL1 into 
the medium by ELISA (Fig. 3-18 [B, C]).  
Flow cytometry revealed that the ADAM10 shRNA knockdown occurred to a similar extent 
for both truncated and untruncated mCX3CL1-expressing HEK293 cells. As shown in the 
figure, the truncated mCX3CL1 variant was again released approximately 3-fold more as the 
wt mCX3CL1. The specific shRNA knockdown for ADAM10 correlated with the reduced 
release of the wt and the truncated mCX3CL1. Specific shRNA knockdown ADAM17, 
however, did not reduce the release of mCX3CL1 and the mCX3CL1 variant, indicating that 
ADAM10 rather than ADAM17 contributes to constitutive shedding of mouse CX3CL1.  
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Fig. 3-18: Release of soluble mCX3CL1 by stable mCX3CL1-HEK293 and mCX3CL1 
trunc-HEK293 cells using ADAM10 and ADAM17 shRNA knockdown 
The previously generated HEK293 cells stably expressing mouse CX3CL1 (mCX3CL1) and 
truncated mouse CX3CL1 (mCX3CL1 trunc) were transduced with specific double stranded 
RNA sequences for ADAM10 and ADAM17 using lentivral derived shRNA knockdown 
technology. [A] Control-shRNA and A10-shRNA transduced mCX3CL1-HEK293 cells and 
mCX3CL1 trunc-HEK293 cells were then screened for ADAM10 surface expression by 
gating for GFP positive cells and a following analysis by flow cytometry using the α-hA10, 
the mouse IgG2B isotype and the α-mouse APC antibodies. The mCX3CL1-HEK293 cells 
[B] and the mCX3CL1 trunc-HEK293 cells [C] were then analysed for the release of soluble 
CX3CL1 by ELISA. Data shown in the diagram are presented as released CX3CL1 in the 
medium. The means and standard deviations (SD) of three independent experiments are 
shown. Statistical analysis was performed using two-way ANOVA followed by Bonferroni 
post-hoc test. The p-values indicated as *, ** were smaller than 0.05, 0.01. 
 
 
As a summary, the release of soluble mCX3CL1 into the medium is influenced by different 
domains distinct from the membrane proximal cleavage sites as shown by experiments using 
transiently transfected HEK293 cells. Truncation of the C-terminal cytoplasmic tail of 
mCX3CL1 showed the most pronounced reduction in the release of soluble CX3CL1 for 
transient transfected cells. However, the truncation does not reduce the release of soluble 
molecules into the conditioned medium, for the stably transfected HEK293 cells upon 
selection for similar surface expression. This release of the truncated mCX3CL1 was also 
shown to be inhibited to a similar degree as the release of the wt mCX3CL1 by shRNA 
knockdown for ADAM10.  
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3.2 The role of mouse CX3CL1 in adhesion and transmigration 
 
In published data the function of human CX3CL1 has been predominately analysed. The 
function of mouse CX3CL1 in adhesion and transmigration remains less understood. Here 
the function of mouse CX3CL1 was analysed in these processes.  
 
 
3.2.1 Adhesion of mouse CX3CL1 
 
As shown in section 3.1 the HEK293 cells stably expressing the wt mouse CX3CL1 and the 
truncated mouse CX3CL1 showed no differences in the constitutive release of soluble 
CX3CL1 mediated by ADAM10. Since the truncated CX3CL1 contain no C-terminal 
cytoplasmic tail, it was speculated that truncation of the cytoplasmic tail could alter the 
function of CX3CL1 as an adhesion molecule, due to an impaired anchoring within the cell 
surface membrane or impaired upstream signalling. It was therefore decided to test the 
adhesion of both mCX3CL1 variants without the influence of the mouse CX3CR1 receptor 
first. 
For this purpose, the HEK293 cells stably expressing the wt and truncated mCX3CL1 were 
seeded onto a 96-well plate that was coated with the rat α-mCX3CL1 antibody (for details 
see section 2.3.8). Before and after several washing steps cell number were calculated upon 
measuring the β-glucoronidase within the cells according to section 2.4.3 (Fig. 3-19). This 
static adhesion assay showed that both truncated and untruncated mCX3CL1 variants 
mediated up to 3-fold increase in adhesion after a single washing step compared to wt 
HEK293 cells serving as control. After three times of washing, 40% of HEK293 cells stably 
expressing the mCX3CL1 variants still remain attached to the antibody whereas the wt 
HEK293 cells were nearly completely detached. However, there was no significant 
difference in adhesion to a coated α-mCX3CL1 antibody after the first washing and the third 
washing observed for the wt mCX3CL1 cells and the cells expressing the truncated 
mCX3CL1 variant. 
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Fig. 3-19: Adhesion of mCX3CL1 and mCX3CL1 trunc  
Wt HEK293 (control), mouse CX3CR1-expressing HEK293 cells (mCX3L1) and truncated 
mouse CX3CL1-expressing HEK293 cells (mCX3CL1 trunc) were seeded onto the rat α-
mCX3CL1 antibody coated 96-well plate using 1,000 g for 1 min before the cells were 
washed up to four times with pre-warmed PBS. The cell number of the first [black] and the 
third [grey] washing step was related to the cell number of the seeded cells and shown in the 
diagram as percent adhered cells. The means and standard deviations (SD) of three 
independent experiments are shown. Statistical analysis was performed using two-way 
ANOVA followed by Bonferroni post-hoc test. The p-values indicated as *, ** were smaller 
than 0.05, 0.01. 
 
 
0
20
40
60
80
control
one washing step
three washing steps
ad
he
re
d
ce
lls
[%
]
mCX3CL1 mCX3CL1 trunc
**
**
ad
he
re
d
ce
lls
[%
]
3.2.2 Transmigration of mouse CX3CL1 
 
The results of the adhesion assay showed the adhesive capacity of the mouse CX3CL1. 
Moreover, the truncated mCX3CL1 was shown above to have no influence on the adhesion 
compared to the wt mCX3CL1. The capacity of mouse CX3CL1 in transmigration still 
remains unclear. Since internal studies in the laboratory of Prof. Dr. Ludwig indicated that 
the human CX3CR1 receptor functionally answers to mouse CX3CL1 by calcium influx, the 
role of both wt and truncated mCX3CL1 variants in the process of leukocyte transmigration 
using human isolated PBMCs was studied 
For the transmigration analysis, a transwell system was established, in which the HEK293 
cells expressing the wt and cells expressing the truncated mCX3CL1 variants functioned as a 
cell monolayer in the upper well. As pre-test, human neutrophils were used which were 
already well established in transmigration assays. They were isolated from blood of three 
different donors aged between 28 to 42 years (for details see section 2.3.2) and then analysed 
for the transmigration potency towards human IL-8 as stimulus in the lower chamber of the 
transwell system containing ECV304 and HEK293 cells as a cell monolayer. From these pre-
experiments HEK293 cells were shown to be of comparable use for the transmigration assay 
as the established ECV304 cells (data not shown). 
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In a second step, human peripheral blood mononuclear cells (PBMCs) expressing the 
receptor CX3CR1 were isolated from blood of three different donors aged around 30 years 
(for details see section 2.3.2). They were examined for the surface expression of the human 
receptor CX3CR1 by flow cytometry (Fig. 3-20 [A, B]).  
In case the surface expression of the CX3CR1 within monocytic population was as high as 
shown in the histogram, the PBMCs were further used for transmigration assays using 
soluble human CX3CL1 and soluble human MCP-1 as stimuli. The number of cells in the 
lower chamber and the number of cells at the beginning of the assay in the upper chamber 
was measured using the β-glucoronidase assay and shown as percent migrated cells. As 
shown in Fig. 3-20 [C, D], CX3CL1 resulted in an approximately 1.5-fold increased 
transmigration rate compared to the non-stimulated control. MCP-1 mediated transmigration 
of human PBMCs was found to be 2-fold increased compared to the non-stimulated control.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-20: Transmigration of PBMCs across wt HEK293 cells by soluble CX3CL1 and 
MCP-1 
[A] The human PBMCs were isolated and screened for CX3CR1 expression by flow 
cytometry using the rat α-hCX3CR1-PE and IgG2bκ-PE isotype antibody. The total cell 
population was gated for monocyte population. [B] The fluorescence intensity of the gated 
population is shown. [C] The PBMCs with a minimum of CX3CR1 expressing rate as shown 
were studied for transmigration for 2.5 h towards 12 nM soluble human CX3CL1 with wt 
HEK293 cells. [D] PBMCs were also studied for transmigration towards 6 nM MCP-1. The 
means and standard deviations (SD) of three independent experiments are shown. Statistical 
analysis was performed using paired two-tailed t-test. The p-values indicated as * were 
smaller than 0.05. 
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The result described above showed that CX3CR1-expressing PBMCs could transmigrate 
across HEK293 cells towards soluble hCX3CL1 as a stimulus. Recent findings showed for 
the first time that transmembrane human CX3CL1 expressed on activated endothial cells 
induces transmigration without soluble CX3CL1 as stimulus85. It was therefore interesting to 
know, whether this effect might also be detectable for the mouse CX3CL1 and whether this 
potential transmembrane CX3CL1-mediated transmigration is affected by the truncation of 
C-terminal cytoplasmic tail.  
For the transmigration assay wt HEK293 cells and HEK293 cells stably expressing 
mCX3CL1 and mCX3CL1 trunc were seeded onto the transwell filter. Isolated human 
PBMCs were then studied for transmigration in the absence of soluble human CX3CL1 (Fig. 
3-21). This experiment showed that the percentage of migrated cell was increased from 
approximately 4% to 7% when HEK293 cells expressed the mCX3CL1 variants. This 
indicates that transmembrane mouse CX3CL1 is able to induce the transmigratory processes 
of human PBMCs. However, there was no significant difference detectable between the 
truncated mCX3CL1 and the un-truncated mCX3CL1 variant. 
 
 
 
 
 
 
 
 
 
 
Fig. 3-21: Transmigration of PBMCs across HEK293 cells by transmembrane mouse 
CX3CL1 
Human Peripheral Blood Mononuclear Cell (PBMCs) were isolated and screened for at least 
moderate CX3CR1 expression rates as shown above. They were then studied for 
transmigration for 2.5 h in the absence of soluble CX3CL1 using wt HEK293 cells and 
HEK293 cells stably expressing mouse CX3CL1 (mCX3CL1) and truncated mouse CX3CL1 
(mCX3CL1 trunc). The means and standard deviations (SD) of three independent 
experiments are shown. Statistical analysis was performed using one-way ANOVA followed 
by Bonferroni post-hoc test. The p-values indicated as * were smaller than 0.05. 
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transmigration induced by soluble CX3CL1, isolated PBMCs were studied for transmigration 
across a HEK293 cell monolayer expressing no mCX3CL1 and both mCX3CL1 variants. 
Additionally, soluble CX3CL1 and soluble MCP-1 were applied in the lower chamber of the 
transwell system. As shown in Fig. 3-22, the percentage of migrated cell upon CX3CL1 
stimulation was around 7-8% for all cell lines, which was approximately 1.5-fold higher than 
the basal transmigration. However, no significant difference between wt HEK293 cells and 
both mCX3CL1 and truncated mCX3CL1 expressing HEK293 cells was detectable. In 
addition, the rate of MCP-1 induced migrated PBMCs across all cell lines was approximately 
equal at around 15%, also showing 2-fold increase compared to basal transmigration. As for 
the induced transmigration by soluble CX3CL1, the MCP-1-mediated transmigration was 
affected neither by wt HEK293 cells, nor by mCX3CL1-HEK293 cells nor by mCX3CL1 
trunc-HEK293 cells.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-22: Transmigration of PBMCs across mCX3CL1 variants expressing HEK293 
cells by soluble CX3CL1 and MCP-1 
Human Peripheral Blood Mononuclear Cell (PBMCs) were isolated and screened for like 
shown above. They were then studied for transmigration for 2.5 h in the presence of 12 nM 
soluble CX3CL1 [A] and 6 nM soluble MCP-1 [B] using wt HEK293 cells and HEK293 cells 
stably expressing mouse CX3CL1 (mCX3CL1) and truncated mouse CX3CL1 (mCX3CL1 
trunc). The means and standard deviations (SD) of three independent experiments are shown. 
Statistical analysis was performed using one-way ANOVA. The dashed line represents the 
basal non-stimulated transmigration across HEK293 as obtained in the previous experiments 
mentioned above. 
 
 
The mCX3CL1 variants with similar surface expression levels were studied for the 
involvement of intracellular cytoplasmic tail of mouse CX3CL1 in adhesion and 
transmigration. The experiments demonstrated that truncation of the cytoplasmic tail of 
CX3CL1 does not affect the function of CX3CL1 in adhesion and transmigration. 
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4 4   DISCUSSION 
 
 
Inflammatory leukocyte recruitment is mediated by many regulators like selectins, 
glycosylated selectin ligands, proteoglycans, chemokines, chemokine receptors, intergrins, 
cellular adhesion molecule as well as cellular junction molecules. Among the large family of 
chemokines that induce directional cell migration an unusual member the CX3CL1 
(fractalkine) is described, existing as a transmembrane mediating adhesion and 
transmigration of leukocytes carrying the receptor CX3CR1. The transmembrane CX3CL1 
can be converted into a soluble form that mediate directional cell migration. Thus, cleavage 
by ADAM protein was proposed and indeed ADAM10 and ADAM17 were shown to cleave 
CX3CL1141,146. However, it remains unclear whether mouse CX3CL1 would undergo a 
similar cleavage and fulfil similar functions as the human CX3CL1. 
To address this, distinct domains in mouse CX3CL1 that mediate cleavage by ADAM10 (and 
ADAM17) and the function of mouse CX3CL1 as an adhesion and a transmigration molecule 
were analysed and were as follows. The release of mouse CX3CL1 also involved ADAM10-
dependent cleavage mechanisms. Transient transfections of HEK293 cells also suggested that 
the constitutive release of mouse CX3CL1 is not only affected by the mucin-like stalk region 
containing the two potential cleavage site, but also by the extracellular chemokine domain, 
the transmembrane domain and the intracellular cytoplasmic tail of mouse CX3CL1. The 
cytoplasmic tail also seems to influence the trafficking of the molecule within the cell. After 
selection for similar surface expression levels, the cytoplasmic tail, however, was shown not 
to be involved in the ADAM10-mediated shedding. Furthermore, it was shown that the 
cytoplasmic tail is not relevant for the function of mouse CX3CL1 as an adhesion and 
transmigration molecule. 
 
 
4.1 Characterisation of mouse CX3CL1 
 
By Western blot analysis, the release of mouse CX3CL1 from transiently transfected human 
HEK293 cells was characterised in comparison to the well known human CX3CL1 release. 
Soluble forms of human and mouse CX3CL1 were shown to be released in the medium of 
the transfected HEK293 cells. For the human CX3CL1 it was reported that a soluble form of 
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approximately 70 kDa results from the shedding of the fully glycosylated mature 
transmembrane form of CX3CL1 (90 kDA)141,146. For mouse CX3CL1 a soluble variant 
slightly smaller than 70 kDa and a cell-associated 90 kDa variant were also detected. 
The smaller mouse CX3CL1 proteins found in the cell lysates may represent not fully 
glycosylated and therefore unmaturated forms of CX3CL1 as they have been already 
described in the literature for human CX3CL152. In studies performed with surface 
biotinylation of a CX3CL1/gp130 chimera it was shown that only the mature form of human 
CX3CL1 is expressed on the surface (Institute of Biochemistry, Christian-Albrecht-
University zu Kiel, AG Ludwig, Diploma thesis by Ulrike Winter). This also suggested that 
the soluble CX3CL1 represents the shed ectodomain of the mature 90 kDa chemokine. In this 
thesis, pharmacological or transcriptional inhibition of endogenous ADAMs was not 
performed, neither the deglycosylation of the smaller cell-associated form of CX3CL1. 
However interestingly, the smaller protein found in the cell lysate differ slightly in size from 
approximately 55 kDa (human) to approximately 60 kDa (mouse). The difference is maybe 
due to differential glycosylation of the human and the mouse CX3CL1 in human embryonic 
kidney cells. 
 
Quantification of released forms of mouse and human CX3CL1 demonstrated that both 
human and mouse CX3CL1 proteolytic cleavage was considerably suppressed by applying 
the inhibitors separately or in combination. Although the inhibitor for ADAM10 (A10, IC50-
ADAM10 5.3 nM) was shown to be the more effective against ADAM10 than the dual-
specific inhibitor for ADAM10 and ADAM17 (A10/17, IC50-ADAM10 11.5 nM)146, the 
results showed that the A10/17 inhibitor more efficiently blocks the release of both human 
and mouse CX3CL1. However, the combinatorial application of both ADAM inhibitors (A10 
and A10/17) resulted in the most significant inhibition. The residual release (one-fourth) of 
human and mouse CX3CL1 forms suggest that other proteolytic cleavage processes could be 
involved in the release of soluble CX3CL1. By the use of iTRAQTM labelling already an 
involvement of the matrix metalloproteinase MMP-2 in the proteolytic cleavage of CX3CL1 
was suggested153. In the brain also cathepsin S was shown to be involved in the release of 
soluble CX3CL1154. These findings could be linked to recent studies on salivary glands, 
which showed the release of a soluble 17 kDA CX3CL1 fragment155. This could suggest that 
the generation of this smaller fragment could be due to further cleavage via MMP-2 or 
cathepsin S. 
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4.2 Analysis the shedding and trafficking of mouse CX3CL1 
 
Cleavage sites for hCX3CL1 
Purification of a 2zHis-tag fused human CX3CL1 molecule led to the identification of three 
C-terminal fragments (CTFs) with an approximate size of 23, 24 and 25 kDa. After 
deglycosylation of the terminal sialic acid residues and unsubstituted galactose disaccharides 
found located in the O-glycosylated mucin-like stalk of CX3CL1, only the two smaller 
fragments were detectable.  
To narrow down the amino acid residues involved in the cleavage the theoretical molecular 
mass of hCX3CL1-2zHis was calculated using a protein calculator (protein calculator v3.3, 
copyright Chris Putman, The Scripps research institute). The cytoplasmic tail and the 
transmembrane region together were calculated to be 22.44 kDa. The juxtamembrane mucin-
like stalk region of human CX3CL1 from amino acid 313 to 341 is described as EPIHATMD 
PQRLGVILTPVPDAQAATRRQ, including the potentially O-glycosylated threonine (T) 
residue at position 329 of the protein and the di-arginine motif (RR) at position 339 to 340. 
The theoretical molecular mass of C-terminal fragments including both arginines was 
calculated to be 22.017 kDa, whereas the fragment including the first threonine residues was 
calculated to be 23.409 kDa. The next possible O-glycosylated threonine residue is located at 
position 318 of the protein, which are 11 amino acids (1.242 kDa) upstream towards the N-
terminus. This suggested that one cleavage site could be located at or in close proximity to 
the RR-motif, as already predicted52 and represented by the 23 kDa CTF1. The second 
cleavage site is very likely to be located between the first two threonine residues (amino 
acids 317 and 329) as indicated by the presence of the 24 kDa CTF2. These results further 
supported the view that only two cleavage sites proximal to the membrane are used for the 
cleavage of CX3CL1. 
In this study the generated construct on the basis of human CX3CL1 was used, because the 
mouse juxtamembrane sequence share great homology (311-EPIHATADPQ 
KLSVILTPVPDTRQAATRRQ-339) to the human sequence as indicated by the non-
underlined amino acids. To clarify the cleavage of mouse CX3CL1 in more detail, a 
constructs generated with this part of mouse CX3CL1 and the 2zHis tag could still be used. 
The ectodomain cleavage of molecules from the cell surface by ADAM proteinases was 
reported to be highly variable and is not dependent on consensus sequences within the 
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cleaved proteins115,116. Hence, cleavage sites for the ADAM10 and/or ADAM17 in the 
CX3CL1 protein cannot be predicted in detail so far.   
 
Cleavage region of mouse CX3CL1 
The deletion of the membrane proximal part of the mucin-like stalk of mCX3CL1 and its 
substitution of the mucin-like stalk of mCX3CL1 by a poly glycine-serine linker resulted in 
similar release rates of soluble mCX3CL1 compared to the wt mCX3CL1. Only the 
substitution of the mucin-like stalk by that of an analogous mouse Ig-like C2-type 3 domain 
CD4 domain showed a slight reduction in the release of the soluble form into the medium.  
The results described in this thesis , however, are contrary to the reported CD4-CX3CL1 
chimeras141, which clearly showed a considerably reduced release into the medium. These 
studies were performed on the basis of earlier studies on the proteoglycan syndecan-1, which 
reported to reduce PMA-induced shedding after substitution of the first 15 juxtamembrane 
amino acids of the syndecan-1 by analogous human CD4156. Furthermore, the exchange of 
the first 45 amino acids of the mucin-like stalk of CX3CL1 to that of analogous human CD4 
sequences resulted in decreased PMA-induced ADAM17-mediated release of the chimera 
into the conditioned medium. However, in the reported literature only exchange of the 
juxtamembrane amino acids 15-30 and 1-45 resulted in a decreased release of soluble 
CX3CL1, which was not the case for the changes of the amino acids 31-45, 1-30 and 1-15141. 
This is also contrary to reports in which mutation of the R-R motif to a S-A motif, located 
within the juxtamembrane amino acids 1-15, resulted in an decreased PMA-induced release 
of the soluble human CX3CL1 into conditioned cell medium74,157.  
 
One reasons for this contradictory data could be that the substitution by CD4 were slightly 
different. In the published study by Garton et al. the juxtamembrane sequence of human CD4 
(352-SKREKAVWV LNPEAGMWQC LLSDSGQVLL ESNIKVLPTW STPVQP-396) was 
used, whereas here the sequence of mouse CD4 (317-MKVA QLNNTLTCEV 
MGPTSPKMRL TLKQENQEAR VSEEQKVVQV VAPETGLWQC LLSEGDKVKM 
DSRIQVLSRG VNQT-394) was used. Both sequences, however, do not share high 
similarity, which might explain the different shedding behaviour.  
Another interesting fact explaining differences in the shedding behaviour is that within the 
studies by Garton et al. human CD4-CX3CL1 chimeras were investigated by the use of PMA 
as an inducer for ADAM17-mediated shedding. Experiments in this thesis were performed in 
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the absence of PMA in order to study rather the constitutive ADAM10-mediated shedding, 
which might also explain the different observations of this thesis and the reported study141.  
Although, mutations of the membrane proximal region of CX3CL1 might prevent ADAM17-
dependent cleavage141, the data in this thesis suggested that constitutive ADAM10-dependent 
shedding may still occur and depend on more determinants than only the membrane proximal 
region. 
 
N-terminal chemokine domain of mouse CX3CL1 
Exchange of the N-terminal chemokine domain to that of CCL5 resulted in an increased 
overall release compared to the wt mCX3CL1. 
The N-terminal chemokine domain was reported to be crucial for binding to the receptor 
CX3CR1 and therefore also crucial for the function as a adhesion molecule for circulating 
leukocytes78,79. In these studies single amino acid residues within the chemokine domain 
were mutated or the total chemokine domain was substituted to that of IL-8, MCP-1 and 
CCL5. However, in these reports the role of the chemokine domain in ADAM10-mediated 
shedding processes was not studied.  
The data presented in this study suggested that the chemokine domain of CX3CL1 could 
even have an inhibitory function for ADAM10. The fact that the overall shedding of this 
CCL5/mCX3CL1 was increased could probably explain reported data showing reduced flow 
adhesion of the CCL5-human CX3CL1 chimera78.    
 
Transmembrane and C-terminal region of mouse CX3CL1 
Substitution of C-terminal part mouse CX3CL1 (from amino acid 262 on) by analogous 
regions of mouse CD4 containing the Ig-like C2-type 3 domain, the transmembrane domain 
and the intracellular C-terminal cytoplasmic tail resulted in increased release compared to wt 
mCX3CL1, which was due to an increase in ADAM10-dependent mechanisms.  
Moreover, this increase release was supported by the findings that mouse CD4 itself was also 
released into the medium. The involvement of ADAM10- and/or ADAM17-mediated 
mechanisms was not further investigated, but could still lead to interesting observation about 
CD4, which seems to be proteolycically processed. This cleavage could be performed by 
proteinases and maybe also in particular by ADAM10 and ADAM17, which would explain 
that shedding of mCX3CL1 still occurs after substitution by analogous CD4 domains. 
 
 
Discussion   71 
Since ADAM10 and its substrate CX3CL1 are molecules expressed on the cell surface and 
contain an intracellular cytoplasmic tail, this tail might be a region of interaction, maybe by 
direct contact or indirectly through binding of adaptor molecules leading to the regulation of 
shedding by ADAM10 and ADAM17. At least for ADAM12 an intracellular interaction with 
an adaptor molecule Eve-1 was shown to regulate the shedding of EGF receptor ligands152.  
 
It was shown by Western blotting that truncation of the intracellular cytoplasmic tail of wt 
mouse CX3CL1 and of the chimeric mouse CX3CL1/CD4 molecule did not affect the correct 
expression on the cell surface. A release of both truncated mCX3CL1 variants was still 
observed. But this reduced release was most pronounced for the truncated mCX3CL1, which 
was due to a reduction of ADAM10-mediated release. Interestingly, the truncation of the 
mCX3CL1/CD4 could not further reduce the release of this molecules compared to the full-
length mCX3CL1/CD4 chimera. This release was shown to be mediated also by ADAM10-
dependent mechanisms. 
From these experiments with transiently transfected cells, it seems that truncation of the 
intracellular cytoplasmic tail blocks the ADAM10-mediated release as shown for the 
mCX3CL1. This corresponded with the findings in this thesis that ionomyin-induced 
ADAM10-activity lead to enhanced shedding of the wt mCX3CL1, but only slightly 
increased the shedding for the truncated mCX3CL1. However, the truncation of mCX3CL1 
did not further reduce the degree of release, indicating that truncation of the cytoplasmic tail 
of CX3CL1 is also not affecting ADAM10 independent proteolytic cleavage by other 
proteinases. The question still rises, what other protein could proteolytically cleave CX3CL1. 
As already mentioned MMP-2 and cathepsin S could be involved in the cleavage of 
CX3CL1153,154. 
 
Analysis of wt and truncated mouse CX3CL1 regarding shedding and trafficking 
Both variants were expressed on the cell surface and could be found within the cells in 
perinuclear golgi-like structures as shown by immunomicroscopy. However, distinct vesicle-
like structures within the cell as observed for the wt CX3CL1 form could not be detected. 
These findings are consistent with current studies, showing that the cargo adaptor protein 
(AP2) binds to the intracellular cytoplasmic tail of human CX3CL1 and is thereby involved 
in the clathrin dependent internalisation of CX3CL1 from the cell surface54. The comparison 
of amino acid sequences of the cytoplasmic tails of human and mouse forms also revealed 
that also mouse CX3CL1 contains an AP2 protein binding motif (360-YQSL-363) suggesting 
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a clathrin dependent internalisation also of the mouse CX3CL1. Furthermore, human 
CX3CL1 was shown to be associated with soluble N-ethylmaleimide-sensitive-factor 
attachment receptor (SNARE) proteins responsible for the fusion of trafficking vesicles57. A 
further hint for the regulation of endocytosis by CX3CL1 was provided by studies with a 
truncated human CX3CL154. This mutant was reported to be expressed in elevated levels on 
the cell surface probably due to an impaired endocytosis. Data of this thesis obtained by 
transient transfection also indicated high expression of truncated CX3CL1. But confocal 
microscopic analysis could not exactly reveal whether trafficking to the cell surface or re-
internalisation of mouse CX3CL1 from the cell surface is affected by truncation of the 
cytoplasmic tail or not. 
 
Cells stably expressing the truncated and the wt mCX3CL1 were then generated and selected 
for similar surface expression levels of CX3CL1. Notably, increased levels of released 
molecules of the truncated mCX3CL1 variant were detected in the cell lysate suggesting an 
altered trafficking upon C-terminal truncation. Furthermore, the released forms of the 
truncated mCX3CL1 were remarkably increased in the medium suggesting that shedding via 
ADAM10 could not be affected upon truncation. Pharmacological targeting of the ADAM10 
by the inhibitor A10 results in similar inhibitory rate for the truncated as for the wt CX3CL1, 
which was contradictory to experiments using transient transfections.  
 
Lentivirally derived short hairpin RNA (shRNA) knockdown technology was used to 
downregulate ADAM10 and ADAM17 in HEK293 stably expressing either the wt or the 
truncated mCX3CL1. Only the specific ADAM10 shRNA knockdown resulted in a 
decreased release of wt and truncated mCX3CL1 in the medium, whereas the specific 
knockdown of ADAM17 did not influence the mCX3CL1 release.  
This is a clear evidence for the involvement of ADAM10 in the constitutive shedding of 
mouse CX3CL1 in human embryonic kidney cells, although it has to be considered that the 
specific ADAM10 and ADAM17 shRNA knockdowns were not totally efficient. Since the 
transcriptional targeting of ADAM10 was not as efficient as the pharmacological targeting it 
has also been considered that the inhibitor for ADAM10 could inhibit other proteinases, 
which could be potentially involved in the shedding of mCX3CL1 (e.g. MMP-2153). 
But still, results on mouse CX3CL1 shedding mediated by ADAM10 are in line with data, 
showing that ADAM10 is responsible for the constitutive shedding of human CX3CL1146, 
whereas ADAM17 could responsible for the PMA-induced shedding of human CX3CL1141. 
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Thus, it can be concluded that in the experiments described above constitutive release of 
mCX3CL1 was mainly mediated by ADAM10-dependent mechanisms. 
Therefore it finally became clear that truncation of the intracellular cytoplasmic tail is not 
affecting the shedding/release of mCX3CL1 by ADAM10, as it was suggested by transient 
transfections of HEK293 cells. 
Therefore, it has to be considered that the reduced release rate of the stable mCX3CL1-
HEK293 cells is not necessarily a result of different release/shedding behaviour, but maybe 
related to a different protein expression level and/or different cellular trafficking behaviour. 
As shown by ELISA for released CX3CL1 in the medium, shedding still occurs to a similar 
degree, regardless of the truncation of the intracellular cytoplasmic tail. 
Despite the mutations in different domains of the CX3CL1 molecules, a non-cleavable and 
even a less-cleavable mouse CX3CL1 variant could not be generated. This is in accordance 
to the fact that no consensus sequence for ADAMs in general, nor for ADAM10 and 
ADAM17 in particular, could be found. This could also support the view that not the 
substrate itself drives the ADAMs to cleave, but maybe more the structural organisation 
within “lipid environment” or maybe just the membrane itself. This idea , however, is still 
contrary to the reported studies on non/less-cleavable L-selectin, TNF-α, in which deletion of 
the amino acids of the juxtamembrane region (7 amino acids for L-selectin, 14 amino acids 
for TNF-α) nearly completely decreased shedding of these molecules mediated by 
ADAM17158,159. Although contrary to the reported study on the mutation of the potential 
cleavage site (R-R to S-A) for CX3CL1, the study by Garton et al. described a reduced 
shedding/release of mutated CX3CL1 to a CD4-CX3CL1 chimeric molecules141. But it has to 
be mentioned that both molecules described above were analysed for PMA-induced shedding 
by ADAM17 and not for constitutive ADAM10-mediated shedding. The relevance of this 
artificial PMA-induced shedding model in a more physiological background, however, can 
still be questioned. 
 
 
4.3 The cytoplasmic tail in the function of mouse CX3CL1 
 
The truncation of the intracellular C-terminal cytoplasmic tail of mouse CX3CL1 had no 
influence on ADAM10-mediated shedding. It was then speculated that the cytoplasmic tail 
could still have an influence on the function of CX3CL1 as a domain mediating adhesion and 
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transmigration, because the cytoplamic tail could either affect anchoring of the molecule 
within the cell membrane or could also affect signalling via potential tyrosine motifs located 
within the cytoplasmic tail function as interaction/ binding motifs for various cellular 
molecules. 
Adhesion of cells expressing the mouse CX3CL1 to an anti-mCX3CL1 antibody was 
increased compared to cells not expressing mouse CX3CL1. However, this increased 
adhesion was not affected by the truncation of  mouse CX3CL1. 
This clearly supported the view that mouse CX3CL1 can also function as an adhesion 
molecule independently of the C-terminus. This proposed function of mouse CX3CL1 
matches with the first description of human CX3CL1, which was reported to be involved in 
the adhesion of leukocyte subsets expressing the receptor CX3CR1. These studies also 
showed that the interaction for the adhesion of the chemokine to its receptor occurs at the N-
terminal chemokine domain and not with the mucin-like stalk78,79. So far the influence of the 
C-terminus in the adhesion process was not investigated. But tyrosine motifs within the 
cytoplasmic tail of the chemokine were proposed to be involved in the binding of adaptor 
molecules involved in cellular trafficking54,57. At least for ADAM12 and EGF receptor 
ligands an adaptor protein Eve-1 was shown to be involved in the cleavage152.  
From the data obtained in this thesis it has to be considered that the intracellular cytoplasmic 
tail, however, is not affecting the function of mouse CX3CL1 as an adhesion molecule. 
 
CX3CL1, which is expressed in the cell membrane, was shown to induce transmigration of 
PBMCs across the cell monolayer. In contrast to MCP-1 the soluble form of CX3CL1 was 
not able to further increase the transmigration rate already mediated by the transmembrane 
form of CX3CL1.  
This  indicates that CX3CL1 as its transmembrane form can induce transmigration 
independent of soluble CX3CL1 acting as a chemotatic stimulus. These results are supported 
by other current studies providing evidence for a Gi-protein signalling dependent 
transmigration of CX3CR1-expressing cells mediated by binding of human transmembrane 
CX3CL1 to its receptor CX3CR185. It can also be considered that mouse CX3CL1 functions 
as a transmigration molecule as it was also shown for human CX3CL1 recruiting several 
leukocyte subpopulations52,71,160. But it also needs to be mentioned that there are other studies 
published demonstrating that soluble MCP-1 induce higher transmigration rate than soluble 
CX3CL161,161,162, as this was also indicated in the experiments in this thesis. 
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Truncation of the intracellular C-cytoplasmic tail did not reduce or increase transmigration of 
PBMCs neither by transmembrane CX3CL1, nor by soluble CX3CL1 and nor by MCP-1.  
This clearly suggests that the cytoplasmic part of mouse CX3CL1 is neither relevant for 
adhesion nor for transmigration in response to transmembrane CX3CL1. The truncation of 
the mouse CX3CL1 had no influence on the ADAM10-mediated shedding. Thus, a 
connection of mCX3CL1 truncation and transmigration across a cell monolayer via 
ADAM10 cannot be drawn. Therefore, shedding of CX3CL1 could still be involved in the 
regulation of this transmigration, which was for example directly shown for the cell junction 
associated molecules VE-cadherin and JAM-A145,163. 
The cytoplasmic tail of CX3CL1 contains tyrosine residues within potential adaptor molecule 
binding sites (360-YQSL-363 & 390-YVLV-393), suggesting their role in signalling events 
and therefore maybe also in the process of transmigration. From these data, however, it 
seems unlikely that also the intracellular signalling events induced by the cytoplasmic tail of 
CX3CL1 contribute to the function of mouse CX3CL1 as an adhesion and a transmigration 
molecule. 
 
Hence, it was shown that mouse CX3CL1 similar to human CX3CL1 is a chemokine 
involved in adhesion on the one hand, and in transmigration on the other hand. Both 
processes are independent of a potential regulation by the intracellular tail as it was shown by 
experiments using a truncated CX3CL1 variant.  
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5 5   CONCLUSIONS AND OUTLOOK 
 
 
In this thesis the determinants involved in the shedding of mouse CX3CL1 by ADAM10 and 
ADAM17 and the role of the intracellular cytoplasmic tail of mouse CX3CL1 for adhesion 
and transmigration was studied. The results obtained in this thesis led to following 
conclusions: 
 
 
1. By pharmacological inhibition, mouse CX3CL1 was shown to be shed by 
ADAM10- (and ADAM17)-mediated mechanisms. Constitutive shedding of mouse 
CX3CL1 predominantly occurs via ADAM10- and not via ADAM17-mediated 
mechanisms. The obtained results confirm published data on human CX3CL1 
shedding mediated by ADAM family proteases. 
 
2. ADAM10-mediated constitutive shedding of mouse CX3CL1 occurs closely to 
the membrane at two cleavage sites, most likely at/close to the R-R motif and 
between the first two membrane proximal threonine residues. This shedding is likely 
to be influenced by multiple determinants such as the chemokine domain, the mucin-
like stalk, as shown by transient transfection of cells with mutated mouse CX3CL1 
chimeras/variants.  
 
3. Truncation of the cytoplasmic tail of mouse CX3CL1 affects cellular 
trafficking as indicated by its absence in vesicular-like structures within the cell. 
 
4. When wt and truncated mouse CX3CL1 were selected for similar surface 
expression levels, ADAM10-mediated shedding was not affected in the absence of 
the cytoplasmic tail. The truncation does also not affect the function of the 
transmembrane mouse CX3CL1 as an adhesion and a transmigration molecule. This 
suggests that signalling events of mouse CX3CL1 are not involved in the regulation 
of the leukocyte transmigration. 
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Fig. 5-1: Shedding and function of mouse CX3CL1   
In this thesis it was demonstrated that mouse CX3CL1 is predominately shed by ADAM10-
dependent mechanisms [1] at two cleavage sites proximal to the membrane [2]. The 
cytoplasmic tail of mouse CX3CL1 affects the cellular trafficking [3], but not the function 
of mouse CX3CL1 in adhesion and transmigration [4]. 
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One open question is still how ADAM10- and ADM17-mediated shedding of CX3CL1, in 
particular mouse CX3CL1, is exactly regulated. The exact cleavage sites for ADAM family 
proteases could be still useful for further studies. By usage of the human CX3CL1-2zHis 
construct, N-terminal sequencing (Edman degradation) of the C-terminal fragments or peptide 
mapping in combination with LC-MS/MS (liquid chromatography with tandem mass 
spectrometry detection) could identify the first amino acids of the CTFs and thereby the 
respective cleavage sites. Same experiments could also be performed with the mouse 
CX3CL1. A point, which is also still not clear, is whether ADAM17 use the same two 
potential cleavage sites, shown to be involved in the constitutive shedding by ADAM10. 
 
It could also still be that the cleavage site itself maybe in combination with other domains 
within the CX3CL1 molecule regulates shedding. And if so, how can these domains now be 
exactly characterised? From the obtained data, which suggest the involvement of multiple 
domains in the shedding process, it seems to be a very difficult task to generate CX3CL1 
molecules constitutively non-cleavable by ADAM10. This is underlined by the fact that all 
published data were performed on mutated molecules (L-selectin, TNF-α and hCX3CL1), 
which were only shown to be resistant against ADAM17-mediated mechanisms. In this 
context, however, it can be questioned, if these PMA-induced shedding by ADAM17 can be 
used as a relevant activator for physiological or patho-physiological shedding events. Apart 
from that, it could still be that also the orientation of the ADAMs and their substrates within 
the membrane (e.g. lipid rafts) drives the cleavage process.  
Another interesting focus could be the targeting of mouse ADAM10 and ADAM17, since all 
performed experiments were pharmacological and transcriptional targeting human ADAM10 
and ADAM17. Since high residual ADAM10- and ADAM17-independent shedding was 
observed in this thesis it could also be worthwhile to screen for further proteinases potentially 
cleaving human and mouse CX3CL1. 
 
The obtained data clearly showed the function of mouse CX3CL1 as an adhesion and a 
transmigration molecule, as this was also shown for the human CX3CL1. Although it was 
found that truncation of mouse CX3CL1 seems to have no influence on the shedding 
behaviour it could be still of interest to see whether pharmacological or transcriptional 
targeting of ADAM10 could have an impact in adhesion or transmigration assays mediated by 
truncated mouse CX3CL1. This could still further answer questions (if and) how shedding of 
mouse CX3CL1-mediated by ADAM10 and ADAM17 is involved in these processes. But 
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since the C-terminus of CX3CL1 is most likely to be not involved in the regulation of these 
processes, it can also be questioned what mechanisms drive adhesion and transmigration. To 
further answer these questions the C-terminus of the ADAMs could also become focus, since 
signalling events could be important on this site.  
Furthermore, these assays could be transferred on the other transmembrane chemokine 
CXCL16, which is also shed by ADAM10 and ADAM17. It would be very interesting to see, 
how the intracellular cytoplasmic tail of CX3CL1 affects shedding by ADAM10 and 
ADAM17 and also its function as an adhesion molecule for leukocytes.  
 
It was indicated in this thesis that transmembrane mouse CX3CL1 can induce transmigration. 
This transmigration which was not further increased by soluble CX3CL1, the function of 
soluble CX3CL1 in transmigration could also be questioned. It would be interesting to see, 
whether the CX3C-chemokine domain presented by proteoglycans could also lead to 
shedding by the ADAMs and/or also can induce transmigration. This could further identify 
the function of this exceptional chemokine presented on endothelial cell by a mucin-like stalk. 
An interaction of the N-terminal chemokine domain of CX3CL1 to its CX3CR1 was already 
shown for the human CX3CL1. To see whether this would be true for the mouse CX3CL1, 
generation of cells stably expressing the CCL5/mCX3CL1 chimeric protein  could be useful.  
 
Interestingly, the C-terminus of mouse CX3CL1 seems to be involved in the trafficking to / 
from the cell surface membrane. To further characterise this involvement in trafficking, 
screening for trafficking vesicles associated molecules like clathrin, snare protein, rab 
proteins, or the early endosomal antigen 1 (EEA1) might be useful. As an example, an 
association of other adhesion molecules with trafficking associated molecules was already 
shown for the interaction of the proteoglycan syndecan-1 with the rab5 molecule, which 
regulated the ectodomain shedding of syndecan-1164.  
 
To further analyse a more physiological setting of leukocyte recruitment within this disease 
with regards to the mouse CX3CL1-CX3CR1 interaction, stable cell lines expressing the 
mouse CX3CL1 could be generated. This could be obtained with the help of lentiviral derived 
gene transduction as this was already successfully shown for the shRNA knockdown of 
ADAM10. This shRNA targeting could be also used to knockdown human CX3CL1 by 
targeting the untranslated regions of the CX3CL1 gene in human umbilical vein endothelial 
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cells (HUVECs) and further reconstitute these cells with the mouse CX3CL1 to generate a 
rather physiological background of primary cells.  
It is clear from the published data that the CX3CL1-CX3CR1 interaction, in addition to other 
chemokine interactions, contributes to the accumulation of monocytes in inflammatory 
associated atherosclerotic lesions. While the study was in progress transgenic mice have been 
recently generated using baculovirus derived gene delivery vectors. The mice either express 
the wt CX3CL1, the soluble chemokine domain of CX3CL1 or the C-terminal truncated 
CX3CL1 under an endogenous gene promoter. These animals could still reveal the role of 
soluble CX3CL1 and the role of the C-terminus of CX3CL1 in progression of diseases such 
as atherosclerosis. 
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6 6   SUMMARY 
 
 
Leukocytes are recruited from the blood vessel wall towards the inflamed tissue. This process 
occurs in multiple steps and is regulated in part by chemokines. Among the large family of 
chemokines that mediate directional cell migration an unusual member the CX3CL1 
(fractalkine) is described existing as a transmembrane and a soluble molecule. The generation 
of this soluble CX3CL1 molecule occurs upon ectodomain shedding by metalloproteinases, in 
particular by ADAM10. By binding to the receptor CX3CR1 the transmembrane CX3CL1 
mediates adhesion and transmigration of leukocytes subpopulations. Up to date, it is not clear 
how ADAM10 contributes to the function of mouse CX3CL1. The goal of this thesis was to 
characterise the molecular determinants of mouse CX3CL1 for shedding and function of this 
molecule. 
Results of this study demonstrated that mouse CX3CL1 is predominately shed by ADAM10-
dependent mechanisms as shown by pharmacological inhibition and transcriptional silencing. 
As described for human CX3CL1, shedding of mouse CX3CL1 is enhanced by ionomycin 
treatment, which also involves ADAM10-activity. Deletion and replacement of the cleavage 
region of mouse CX3CL1 could not further abrogate its release suggesting that other domains 
of mouse CX3CL1 may influence this process. And indeed, release of mouse CX3CL1 was 
found to be further influenced by the chemokine domain and also the cytoplasmic tail. 
However, truncation of the cytoplasmic tail led also to impaired cellular trafficking. In fact, 
when wt mouse CX3CL1 and the truncated variant were sufficiently expressed on the cell 
surface, both were still shed. Additionally, adhesion and transmigration experiments with 
human PBMCs revealed that the truncation did not affect the function of the transmembrane 
mouse CX3CL1 as an adhesion and a transmigration molecule. This latter finding suggests 
that potential signalling events induced by the cytoplasmic tail of CX3CL1 are not involved in 
the recruitment of leukocytes to the inflamed tissue. 
This work indicates that multiple molecular determinants within mouse CX3CL1 influence its 
shedding via ADAM10, suggesting that exchange of several domains of mouse CX3CL1 
cannot completely prevent its shedding. The cytoplasmic tail of mouse CX3CL1 appears to be 
relevant for correct trafficking of mouse CX3CL1 but neither for shedding, adhesion or 
transmigration. Nevertheless, shedding of CX3CL1 by ADAM10 and ADAM17 could still 
represent a crucial step within the leukocyte recruitment process in developing vascular 
diseases such as atherosclerosis.  
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α    alpha 
A10   inhibitor of ADAM10 
A10/17   inhibitor of ADAM10 and ADAM17 
ADAM   a disintegrin and metalloproteinase 
ampR   ampicillin resistance 
ANOVA  analysis of variances  
AP2   adaptor protein-2 
APC   allophycocyanin 
ApoE   appolipoprotein E 
APP   amyloid precursor protein 
APS   ammonium persulphate 
ATP   adenosine triphosphate 
β    beta 
bp(s)   base pairs 
BSA   bovine serum albumine 
Ca++   calcium 
CaCl2   calcium chloride 
cDNA   complementary DNA 
CNS   central nervous system 
CR   cysteine rich 
CTF   c-terminal fragment 
°C   degrees Celsius  
Da   dalton 
DAPI   4’, 6-Diamidino-2-phenylindole 
DMEM   Dulbecco’s modified Eagle’s medium  
DMSO   dimethyl sulphoxide 
DNA   deoxyribonucleic acid 
E. coli   Escheririchia coli 
ECL   enhanced chemiluminescence 
EDTA   ethylenediamine tetra-acetic acid 
EEA1   early endosomal antigen-1 
EGF   epidermal growth factor 
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ELISA   enzyme-linked immunosorbent assay 
ERK   extracellular-signal regulated kinase 
EtOH   ethanol 
FCS   fetal calf serum 
FITC   fluorescein isothiocyanate 
FKN   fractalkine 
γ    gamma 
g    g-force  
G-CSF   granulocyte-colony stimulating factor 
GDP   guanosine diphosphate 
GFP   green fluorescent protein 
gp130   glycoprotein 130 
GPCRs   G-protein coupled receptors 
GTP    guanosine triphosphate 
H2O   water  
HEK   human embryonic kidney 
HRP   horseradish peroxidase  
h    hours 
HSPG   heparan-sulphate proteoglycan 
IC   inhibitory concentration 
ICAM    inter-cellular adhesion molecule 
IFN   interferon 
IL   interleukin  
Ig   immunoglobulin 
IP3   inositol triphosphat 
kDa   kilodalton 
KCl   potassium chloride 
KH2PO4   potassium di-hrydogen orthophosphate 
KHCO3   potassium hydrogen carbonate 
LB   lysogeny broth 
LFA-1   lymphocyte-function associated antigen-1 
M   molar 
mA   milliamps 
MAB   monoclonal antibody 
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MCP-1   monocyte chemoattractant protein-1 
MCS   multiple cloning site 
MgCl2   magnesium chloride  
MgSO4   magnesium sulphate 
min   minutes  
ml   millilitre 
µg   microgram 
µl   microlitre 
mM   millimolar 
MMP   matrix metalloproteinase 
MP   metalloproteinase 
mRNA   messenger RNA 
N   normality 
Ni   nickel 
NH4Cl   ammonium chloride 
NaCl   sodium chloride 
Na2HPO4  di-sodium hydrogen orthophosphate 
NaH2PO4  sodium di-hydrogen orthophosphate 
NK   natural killer 
neoR   neomycin resistance   
nm   nanometre 
OD   optical density 
p    probability 
PAGE   polyacrylamide gel electrophoresis 
PBMCs   periphal blood mononuclear cell 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PD   prodomain 
PDVF   polyvinylidene fluoride 
PE   phycoerythrin 
PECAM   platelet/endothelial cell adhesion molecule 
PFA   paraformaldehyd 
PIP2   phosphatidylinositol 4,5-bisphosphate 
PLC   phospolipase C 
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PKC   protein kinase C 
PMA   phorbol 12-myristate 13-acetate 
PrP   prion protein 
PSGL-1   p-selection glycoprotein ligand-1 
RNA   ribonucleic acid 
rpm   revolutions per minute 
rcf   relative centrifugal force 
SD   standard deviation 
SDS   sodium docecyl sulphate 
s    second 
shRNA   short hairpin ribonucleic acid 
SNARE   soluble N-ethylmaleimide-sensitive-factor 
attachment receptor 
TACE   tumor necrosis factor-alpha converting enzyme 
TEMED   N,N,N’,N’-tetramethylene-ethylenediamine 
TGF   transforming growth factor 
TNF-α   tumor necrosis factor-alpha 
Tris   tris (hydroxymethyl) aminomethane 
Tween20  polyoxyethylenesorbitan monolaurate 
U   units 
V   volts 
VCAM   vascular cell adhesion molecule 
VLA-4   very late antigen-4 
wt   wildtype 
Zn   zinc  
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Sup.-Fig. 1a: Map of the mouse CX3CL1  
(mCX3CL1_3.1+)  expression vector 
 
    
 
 
 
     EcoRI                      ןP →+1  
GAATTCGCCACCATGGCTCCCTCGCCGCTCGCGTGGCTGCTGCGCCTGGCCGCGTTCTTCCATTT
GTGTACTCTGCTGCCGGGTCAGCACCTCGGCATGACGAAATGCGAAATCATGTGCGACAAGATGA
CCTCACGAATCCCAGTGGCTTTGCTCATCCGCTATCAGCTAAACCAGGAGTCCTGCGGCAAGCGT
GCCATTGTCCTGGAGACGACACAGCACAGACGCTTCTGTGCTGACCCGAAGGAGAAATGGGTCCA
AGACGCCATGAAGCATCTGGATCACCAGGCTGCTGCCCTCACTAAAAATGGTGGCAAGTTTGAGA
AGCGGGTGGACAATGTGACACCTGGGATCACCTTGGCCACTAGGGGACTGTCCCCATCTGCCCTG
ACAAAGCCTGAATCCGCCACATTGGAAGACCTTGCTTTGGAACTGACTACTATTTCCCAGGAGGC
CAGGGGGACCATGGGGACTTCCCAAGAGCCACCGGCAGCAGTGACCGGATCATCTCTCTCAACTT
CCGAGGCACAGGATGCAGGGCTTACGGCTAAGCCTCAGAGCATTGGAAGTTTTGAGGCGGCTGAC
ATCTCCACCACCGTTTGGCCGAGTCCTGCTGTCTACCAATCTGGATCTAGCTCCTGGGCTGAGGA
AAAAGCTACTGAGTCCCCCTCCACTACAGCCCCATCTCCTCAGGTGTCCACTACTTCACCTTCAA
CCCCAGAGGAAAATGTTGGGTCCGAAGGCCAACCCCCATGGGTCCAGGGACAGGACCTCAGTCCA
GAGAAGTCTCTAGGGTCTGAGGAGATAAACCCAGTTCATACTGATAATTTCCAGGAGAGGGGGCC
TGGCAACACAGTCCACCCCTCAGTGGCTCCCATCTCCTCTGAAGAGACCCCCAGCCCAGAGCTGG
TGGCCTCGGGCAGCCAGGCTCCTAAGATAGAGGAACCCATCCATGCCACTGCAGATCCCCAGAAA
CTGAGTGTGCTTATCACTCCTGTCCCCGACACCCAGGCAGCCACAAGGAGGCAGGCAGTGGGGCT
ACTGGCTTTCCTTGGTCTTCTTTTCTGCCTAGGGGTGGCCATGTTTGCTTACCAGAGCAGAGCCT
TCAGGGCTGTCCCCGCAAAATGGCGGGGGAAATGGTAGAAGGCCTCCGCTACGTCCCCCGTAGCT
GTGGCAGTAACTCATACGTCCTGGTGCCAGTGTGACTCGAG 
           Stop   XhoI  
 
Sup.-Fig. 1b: Sequence of mouse CX3CL1 
 
mCX3CL1 wt_3.1+
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Sup.-Fig. 2a: Map of the mouse CX3CL1/poly-L and mouse CX3CL1/CD4 
(mCX3CL1/CD4_3.1+, mCX3CL1/poly-L)  expression vectors 
 
 
 
 
  EcoRI                    ןP →+1  
GAATTCGCCACCATGGCTCCCTCGCCGCTCGCGTGGCTGCTGCGCCTGGCCGCGTTCTTCCATTT
GTGTACTCTGCTGCCGGGTCAGCACCTCGGCATGACGAAATGCGAAATCATGTGCGACAAGATGA
CCTCACGAATCCCAGTGGCTTTGCTCATCCGCTATCAGCTAAACCAGGAGTCCTGCGGCAAGCGT
GCCATTGTCCTGGAGACGACACAGCACAGACGCTTCTGTGCTGACCCGAAGGAGAAATGGGTCCA
AGACGCCATGAAGCATCTGGATCACCAGGCTGCTGCCCTCACTAAAAATGGTGGCAAGTTTGAGA
AGCGGGTGGACAATGTGACACCTGGGATCACCTTGGCCACTAGGGGACTGTCCCCATCTGCCCTG
ACAAAGCCTGAATCCGCCACATTGGAAGACCTTGCTTTGGAACTGACTACTATTTCCCAGGAGGC
CAGGGGGACCATGGGGACTTCCCAAGAGCCACCGGCAGCAGTGACCGGATCATCTCTCTCAACTT
CCGAGGCACAGGATGCAGGGCTTACGGCTAAGCCTCAGAGCATTGGAAGTTTTGAGGCGGCTGAC
ATCTCCACCACCGTTTGGCCGAGTCCTGCTGTCTACCAATCTGGATCTAGCTCCTGGGCTGAGGA
AAAAGCTACTGAGTCCCCCTCCACTACAGCCC 
    Eco81I        
CATCTCCTCAGGTGTCCACTACTTCACCTTCAACCCCAGAGGAAAATGTTGGGTCCGAAGGCCAA
CCCCCATGGGTCCAGGGACAGGACCTCAGTCCAGAGAAGTCTCTAGGGTCTAAAGTGGCTCAGCT
CAACAATACTTTGACCTGTGAGGTGATGGGACCTACCTCTCCCAAGATGAGACTGACCCTGAAGC
AGGAGAACCAGGAGGCCAGGGTCTCTGAGGAGCAGAAAGTAGTTCAAGTGGTGGCCCCTGAGACA
GGGCTGTGGCAGTGTCTACTGAGTGAAGGTGATAAGGTCAAGATGGACTCCAGGATCCAGGTTTT
ATCCAGAGGGGTGAACCAGACAGCAGTGGGGCTACTGGCTTTCCTTGGTCTTCTTTTCTGCCTAG
GGGTGGCCATGTTTGCTTACCAGAGCCTTCAGGGCTGTCCCCGCAAAATGGCGGGGGAAATGGTA
GAAGGCCTCCGCTACGTCCCCCGTAGCTGTGGCAGTAACTCATACGTCCTGGTGCCAGTGTGACT
CGAG 
 Stop    XhoI 
 
 
Sup.-Fig. 2b: Sequence of mouse CX3CL1/CD4 (CD4 sequence in bold) 
 
mCX3CL1/
CD4 or poly-L
mCX3CL1/CD4_3.1+
mCX3CL1/poly-L_3.1+
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    EcoRI                     ןP →+1  
GAATTCGCCACCATGGCTCCCTCGCCGCTCGCGTGGCTGCTGCGCCTGGCCGCGTTCTTCCATTT
GTGTACTCTGCTGCCGGGTCAGCACCTCGGCATGACGAAATGCGAAATCATGTGCGACAAGATGA
CCTCACGAATCCCAGTGGCTTTGCTCATCCGCTATCAGCTAAACCAGGAGTCCTGCGGCAAGCGT
GCCATTGTCCTGGAGACGACACAGCACAGACGCTTCTGTGCTGACCCGAAGGAGAAATGGGTCCA
AGACGCCATGAAGCATCTGGATCACCAGGCTGCTGCCCTCACTAAAAATGGTGGCAAGTTTGAGA
AGCGGGTGGACAATGTGACACCTGGGATCACCTTGGCCACTAGGGGACTGTCCCCATCTGCCCTG
ACAAAGCCTGAATCCGCCACATTGGAAGACCTTGCTTTGGAACTGACTACTATTTCCCAGGAGGC
CAGGGGGACCATGGGGACTTCCCAAGAGCCACCGGCAGCAGTGACCGGATCATCTCTCTCAACTT
CCGAGGCACAGGATGCAGGGCTTACGGCTAAGCCTCAGAGCATTGGAAGTTTTGAGGCGGCTGAC
ATCTCCACCACCGTTTGGCCGAGTCCTGCTGTCTACCAATCTGGATCTAGCTCCTGGGCTGAGGA
AAAAGCTACTGAGTCCCCCTCCACTACAGCCC 
     Eco81I      
CATCTCCTCAGGTGTCCACTACTTCACCTTCAACCCCAGAGGAAAATGTTGGGTCCGAAGGCCAA
CCCCCATGGGTCCAGGGACAGGACCTCAGTCCAGAGAAGTCTCTAGGGTCTGAGGAGATAAACCC
AGTTCATACTGATAATTTCCAGGAGAGGGGGCCTGGCAACACAGTCCACCCCTCAG 
                            BamHI      
TGGCTCCCATCGGATCCGGAGGTGGGTCATCTGGAAGAAGCGGTGGCGGTGGGAGTTCAGGCGGG
GAAAGCGGAGGCGGGTCTGGAGGTGGCGGAGAGGGAGGCTCAGGAGGTGGGAGCGGGAG 
 BamHI   
TGGAGGGTCTAGAGGATCGGGAGGTGGGAGCGGATCCGCAGTGGGGCTACTGGCTTTCCTTGGTC
TTCTTTTCTGCCTAGGGGTGGCCATGTTTGCTTACCAGAGCCTTCAGGGCTGTCCCCGCAAAATG
GCGGGGGAAATGGTAGAAGGCCTCCGCTACGTCCCCCGTAGCTGTGGCAGTAACTCATACGTCCT
GGTGCCAGTGTGACTCGAG 
                             Stop    XhoI  
 
 
Sup.-Fig. 2c: Sequence of mouse CX3CL1/poly-L (poly-L sequence in bold) 
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Sup.-Fig. 3a: Map of the mouse CX3CL1 del  
(mCX3CL1del_3.1+) expression vector 
 
 
 
 
 
  EcoRI                   ןP →+1  
GAATTCGCCACCATGGCTCCCTCGCCGCTCGCGTGGCTGCTGCGCCTGGCCGCGTTCTTCCATTT
GTGTACTCTGCTGCCGGGTCAGCACCTCGGCATGACGAAATGCGAAATCATGTGCGACAAGATGA
CCTCACGAATCCCAGTGGCTTTGCTCATCCGCTATCAGCTAAACCAGGAGTCCTGCGGCAAGCGT
GCCATTGTCCTGGAGACGACACAGCACAGACGCTTCTGTGCTGACCCGAAGGAGAAATGGGTCCA
AGACGCCATGAAGCATCTGGATCACCAGGCTGCTGCCCTCACTAAAAATGGTGGCAAGTTTGAGA
AGCGGGTGGACAATGTGACACCTGGGATCACCTTGGCCACTAGGGGACTGTCCCCATCTGCCCTG
ACAAAGCCTGAATCCGCCACATTGGAAGACCTTGCTTTGGAACTGACTACTATTTCCCAGGAGGC
CAGGGGGACCATGGGGACTTCCCAAGAGCCACCGGCAGCAGTGACCGGATCATCTCTCTCAACTT
CCGAGGCACAGGATGCAGGGCTTACGGCTAAGCCTCAGAGCATTGGAAGTTTTGAGGCGGCTGAC
ATCTCCACCACCGTTTGGCCGAGTCCTGCTGTCTACCAATCTGGATCTAGCTCCTGGGCTGAGGA
AAAAGCTACTGAGTCCCCCTCCACTACAGCCCCATCTCCTCAGGTGTCCACTACTTCACCTTCAA
CCCCAGAGGAAAATGTTGGGTCCGAAGGCCAACCCCCATGGGTCCAGGGACAGGACCTCAGTCCA
GAGAAGTCTCTAGGGTCTGAGGAGATAAACCCAGTTCATACTGATAATTTCCAGGAGAGGGGGCC
TGGCAACACAGTCCACCCCTCAG 
 BamHI 
TGGCTCCCATCGGATCCGCAGTGGGGCTACTGGCTTTCCTTGGTCTTCTTTTCTGCCTAGGGGTG
GCCATGTTTGCTTACCAGAGCCTTCAGGGCTGTCCCCGCAAAATGGCGGGGGAAATGGTAGAAGG
CCTCCGCTACGTCCCCCGTAGCTGTGGCAGTAACTCATACGTCCTGGTGCCAGTGTGACTCGAG 
      Stop    XhoI  
 
 
Sup.-Fig. 3b: Sequence of mouse CX3CL1 del 
 
mCX3CL1del_3.1+ mCX3CL1
del
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Sup.-Fig. 4a: Map of the CCL5/mouse CX3CL1  
(CCL5/mCX3CL1_3.1+) expression vector 
 
 
 
 
    EcoRI                     ןP →+1  
GAATTCGCCACCATGAAGGTCTCCGCGGCAGCCCTCGCTGTCATCCTCATTGCTACTGCCCTCTGCGC
TCCTGCATCTGCCTCCCCATATTCCTCGGACACCACACCCTGCTGCTTTGCCTACATTGCCCGCCCAC
TGCCCCGTGCCCACATCAAGGAGTATTTCTACACCAGTGGCAAGTGCTCCAACCCAGCAGTCGTCTTT
GTCACCCGAAAGAACCGCCAAGTGTGTGCCAACCCAGAGAAGAAATGGGTTCGGGA 
         AgeI      
GTACATCAACTCTTTGGAGATGAGCACCGGTGGCAAGTTTGAGAAGCGGGTGGACAATGTGACACCTG
GGATCACCTTGGCCACTAGGGGACTGTCCCCATCTGCCCTGACAAAGCCTGAATCCGCCACATTGGAA
GACCTTGCTTTGGAACTGACTACTATTTCCCAGGAGGCCAGGGGGACCATGGGGACTTCCCAAGAGCC
ACCGGCAGCAGTGACCGGATCATCTCTCTCAACTTCCGAGGCACAGGATGCAGGGC 
     PflMI      
TTACGGCTAAGCCTCAGAGCATTGGAAGTTTTGAGGCGGCTGACATCTCCACCACCGTTTGGCCGAGT
CCTGCTGTCTACCAATCTGGATCTAGCTCCTGGGCTGAGGAAAAAGCTACTGAGTCCCCCTCCACTAC
AGCCCCATCTCCTCAGGTGTCCACTACTTCACCTTCAACCCCAGAGGAAAATGTTGGGTCCGAAGGCC
AACCCCCATGGGTCCAGGGACAGGACCTCAGTCCAGAGAAGTCTCTAGGGTCTGAGGAGATAAACCCA
GTTCATACTGATAATTTCCAGGAGAGGGGGCCTGGCAACACAGTCCACCCCTCAGTGGCTCCCATCTC
CTCTGAAGAGACCCCCAGCCCAGAGCTGGTGGCCTCGGGCAGCCAGGCTCCTAAGATAGAGGAACCCA
TCCATGCCACTGCAGATCCCCAGAAACTGAGTGTGCTTATCACTCCTGTCCCCGACACCCAGGCAGCC
ACAAGGAGGCAGGCAGTGGGGCTACTGGCTTTCCTTGGTCTTCTTTTCTGCCTAGGGGTGGCCATGTT
TGCTTACCAGAGCAGAGCCTTCAGGGCTGTCCCCGCAAAATGGCGGGGGAAATGGTAGAAGGCCTCCG
CTACGTCCCCCGTAGCTGTGGCAGTAACTCATACGTCCTGGTGCCAGTGTGACTCGAG 
            Stop   XhoI  
 
 
    Sup.-Fig. 4b: Sequence of CCL5/mouse CX3CL1 (CCL5 sequence in bold) 
 
CCL5/
mCX3CL1_3.1+
CCL5/
mCX3CL1
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Sup.-Fig. 5a: Map of the mouse CX3CL1/CD4 fusion (mCX3CL1/CD4fusion_3.1+) 
expression vector 
 
 
 
 
 
  EcoRI                   ןP →+1  
GAATTCGCCACCATGGCTCCCTCGCCGCTCGCGTGGCTGCTGCGCCTGGCCGCGTTCTTCCATT
TGTGTACTCTGCTGCCGGGTCAGCACCTCGGCATGACGAAATGCGAAATCATGTGCGACAAGAT
GACCTCACGAATCCCAGTGGCTTTGCTCATCCGCTATCAGCTAAACCAGGAGTCCTGCGGCAAG
CGTGCCATTGTCCTGGAGACGACACAGCACAGACGCTTCTGTGCTGACCCGAAGGAGAAATGGG
TCCAAGACGCCATGAAGCATCTGGATCACCAGGCTGCTGCCCTCACTAAAAATGGTGGCAAGTT
TGAGAAGCGGGTGGACAATGTGACACCTGGGATCACCTTGGCCACTAGGGGACTGTCCCCATCT
GCCCTGACAAAGCCTGAATCCGCCACATTGGAAGACCTTGCTTTGGAACTGACTACTATTTCCC
AGGAGGCCAGGGGGACCATGGGGACTTCCCAAGAGCCACCGGCAGCAGTGACCGGATCATCTCT
CTCAACTTCCGAGGCACAGGATGCAGGGCTTACGGCTAAGCCTCAGAGCATTGGAAGTTTTGAG
GCGGCTGACATCTCCACCACCGTTTGGCCGAGTCCTGCTGTCTACCAATCTGGATCTAGCTCCT
GGGCTGAGGAAAAAGCTACTGAGTCCCCCTCCACTACAGCCCCATCTCCTCAGGTGTCCACTAC
TTCACCTTCAACCCCAGAGGAAAATGTTGGGTCCGAAGGCCAACCCCCATGGGTCCAGGGACAG
GACCTCAGTCCAGAGAAGTCTCTAGGGTCTAAAGTGGCTCAGCTCAACAATACTTTGACCTGTG
AGGTGATGGGACCTACCTCTCCCAAGATGAGACTGACCCTGAAGCAGGAGAACCAGGAGGCCAG
GGTCTCTGAGGAGCAGAAAGTAGTTCAAGTGGTGGCCCCTGAGACAGGGCTGTGGCAGTGTCTA
CTGAGTGAAGGTGATA 
  BamHI 
AGGTCAAGATGGACTCCAGGATCCAGGTTTTATCCAGAGGGGTGAACCAGACAGTGTTCCTGGC
TTGCGTGCTGGGTGGCTCCTTCGGCTTTCTGGGTTTCCTTGGGCTCTGCATCCTCTGCTGTGTC
AGGTGCCGGCACCAACAGCGCCAGGCAGCACGAATGTCTCAGATCAAGAGGCTCCTCAGTGAGA
AGAAGACCTGCCAGTGCCCCCACCGGATGCAGAAGAGCCATAATCTCATCTGACTCGAG 
Stop XhoI  
 
Sup.-Fig. 5b: Sequence of mouse CX3CL1/CD4 fusion (CD4 sequence in bold) 
mCX3CL1/CD4
fusion_3.1+ mCX3CL1/
CD4 fusion
, BamHI
 
Supplements   105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sup.-Fig. 6a: Map of the mouse CD4 
(mCD4_3.1+) expression vector 
 
 
 
EcoRI                     ןP →+1  
GAATTCGCCACCATGTGCCGAGCCATCTCTCTTAGGCGCTTGCTGCTGCTGCTGCTGCAGCTGTCAC
AACTCCTAGCTGTCACTCAAGGGAAGACGCTGGTGCTGGGGAAGGAAGGGGAATCAGCAGAACTGCC
CTGCGAGAGTTCCCAGAAGAAGATCACAGTCTTCACCTGGAAGTTCTCTGACCAGAGGAAGATTCTG
GGGCAGCATGGCAAAGGTGTATTAATTAGAGGAGGTTCGCCTTCGCAGTTTGATCGTTTTGATTCCA
AAAAAGGGGCATGGGAGAAAGGATCGTTTCCTCTCATCATCAATAAACTTAAGATGGAAGACTCTCA
GACTTATATCTGTGAGCTGGAGAACAGGAAAGAGGAGGTGGAGTTGTGGGTGTTCAAAGTGACCTTC
AGTCCGGGTACCAGCCTGTTGCAAGGGCAGAGCCTGACCCTGACCTTGGATAGCAACTCTAAGGTCT
CTAACCCCTTGACAGAGTGCAAACACAAAAAGGGTAAAGTTGTCAGTGGTTCCAAAGTTCTCTCCAT
GTCCAACCTAAGGGTTCAGGACAGCGACTTCTGGAACTGCACCGTGACCCTGGACCAGAAAAAGAAC
TGGTTCGGCATGACACTCTCAGTGCTGGGTTTTCAGAGCACAGCTATCACGGCCTATAAGAGTGAGG
GAGAGTCAGCGGAGTTCTCCTTCCCACTCAACTTTGCAGAGGAAAACGGGTGGGGAGAGCTGATGTG
GAAGGCAGAGAAGGATTCTTTCTTCCAGCCCTGGATCTCCTTCTCCATAAAGAACAAAGAGGTGTCC
GTACAAAAGTCCACCAAAGACCTCAAGCTCCAGCTGAAGGAAACGCTCCCACTCACCCTCAAGATAC
CCCAGGTCTCGCTTCAGTTTGCTGGTTCTGGCAACCTGACTCTGACTCTGGACAAAGGGACACTGCA
TCAGGAAGTGAACCTGGTGGTGATGAAAGTGGCTCAGCTCAACAATACTTTGACCTGTGAGGTGATG
GGACCTACCTCTCCCAAGATGAGACTGACCCTGAAGCAGGAGAACCAGGAGGCCAGGGCTCTGAGGA
GCAGAAAGTAGTTCAAGTGGTGGCCCCTGAGACAGGGCTGTGGCAGTGTCTACTGAGTGAAGGTGAT
AAGGTCAAGATGG 
                BamHI 
ACTCCAGGATCCAGGTTTTATCCAGAGGGGTGAACCAGACAGTGTTCCTGGCTTGCGTGCTGGGTGG
CTCCTTCGGCTTTCTGGGTTTCCTTGGGCTCTGCATCCTCTGCTGTGTCAGGTGCCGGCACCAACAG
CGCCAGGCAGCACGAATGTCTCAGATCAAGAGGCTCCTCAGTGAGAAGAAGACCTGCCAGTGCCCCC
ACCGGATGCAGAAGAGCCATAATCTCATCTGATGACTCGAG 
                                                                                                Stop   XhoI 
 
Sup.-Fig. 6b: Sequence of mouse CD4 
 
 
mCD4_3.1+
mCD4
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Sup.-Fig. 7a: Map of the mouse CX3CL1 trunc  
(mCX3CL1 trunc_3.1+) expression vector 
 
 
 
 
EcoRI                     ןP →+1  
GAATTCGCCACCATGGCTCCCTCGCCGCTCGCGTGGCTGCTGCGCCTGGCCGCGTTC 
TTCCATTTGTGTACTCTGCTGCCGGGTCAGCACCTCGGCATGACGAAATGCGAAATC 
ATGTGCGACAAGATGACCTCACGAATCCCAGTGGCTTTGCTCATCCGCTATCAGCTA 
AACCAGGAGTCCTGCGGCAAGCGTGCCATTGTCCTGGAGACGACACAGCACAGACGC 
TTCTGTGCTGACCCGAAGGAGAAATGGGTCCAAGACGCCATGAAGCATCTGGATCAC 
CAGGCTGCTGCCCTCACTAAAAATGGTGGCAAGTTTGAGAAGCGGGTGGACAATGTG 
ACACCTGGGATCACCTTGGCCACTAGGGGACTGTCCCCATCTGCCCTGACAAAGCCT 
GAATCCGCCACATTGGAAGACCTTGCTTTGGAACTGACTACTATTTCCCAGGAGGCC 
AGGGGGACCATGGGGACTTCCCAAGAGCCACCGGCAGCAGTGACCGGATCATCTCTC 
TCAACTTCCGAGGCACAGGATGCAGGGCTTACGGCTAAGCCTCAGAGCATTGGAAGT 
    PflMI 
TTTGAGGCGGCTGACATCTCCACCACCGTTTGGCCGAGTCCTGCTGTCTACCAATCT 
GGATCTAGCTCCTGGGCTGAGGAAAAAGCTACTGAGTCCCCCTCCACTACAGCCCCA 
TCTCCTCAGGTGTCCACTACTTCACCTTCAACCCCAGAGGAAAATGTTGGGTCCGAA 
GGCCAACCCCCATGGGTCCAGGGACAGGACCTCAGTCCAGAGAAGTCTCTAGGGTCT 
GAGGAGATAAACCCAGTTCATACTGATAATTTCCAGGAGAGGGGGCCTGGCAACACA 
GTCCACCCCTCAGTGGCTCCCATCTCCTCTGAAGAGACCCCCAGCCCAGAGCTGGTG 
GCCTCGGGCAGCCAGGCTCCTAAGATAGAGGAACCCATCCATGCCACTGCAGATCCC 
CAGAAACTGAGTGTGCTTATCACTCCTGTCCCCGACACCCAGGCAGCCACAAGGAGG 
CAGGCAGTGGGGCTACTGGCTTTCCTTGGTCTTCTTTTCTGCCTAGGGGTGGCCATG 
TTTGCTTACCAGAGCTGACTCGAG 
     Stop   XhoI  
 
 
Sup.-Fig. 7b: Sequence of mouse CX3CL1 trunc 
mCX3CL1     
trunc_3.1+
mCX3CL1
trunc
6496 bp
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Sup.-Fig. 8a: Map of the mouse CX3CL1/CD4 trunc  
(mCX3CL1/CD4 trunc_3.1+) expression vector 
 
 
 
EcoRI                     ןP →+1
GAATTCGCCACCATGGCTCCCTCGCCGCTCGCGTGGCTGCTGCGCCTGGCCGCGTTCTTC
CATTTGTGTACTCTGCTGCCGGGTCAGCACCTCGGCATGACGAAATGCGAAATCATGTGC
GACAAGATGACCTCACGAATCCCAGTGGCTTTGCTCATCCGCTATCAGCTAAACCAGGAG
TCCTGCGGCAAGCGTGCCATTGTCCTGGAGACGACACAGCACAGACGCTTCTGTGCTGAC
CCGAAGGAGAAATGGGTCCAAGACGCCATGAAGCATCTGGATCACCAGGCTGCTGCCCTC
ACTAAAAATGGTGGCAAGTTTGAGAAGCGGGTGGACAATGTGACACCTGGGATCACCTTG
GCCACTAGGGGACTGTCCCCATCTGCCCTGACAAAGCCTGAATCCGCCACATTGGAAGAC
CTTGCTTTGGAACTGACTACTATTTCCCAGGAGGCCAGGGGGACCATGGGGACTTCCCAA
GAGCCACCGGCAGCAGTGACCGGATCATCTCTCTCAACTTCCGAGGCACAGGATGCAGGG
CTTACGGCTAAGCCTCAGAGCATTGGAAGT 
      PflMI 
TTTGAGGCGGCTGACATCTCCACCACCGTTTGGCCGAGTCCTGCTGTCTACCAATCTGGA
TCTAGCTCCTGGGCTGAGGAAAAAGCTACTGAGTCCCCCTCCACTACAGCCCCATCTCCT
CAGGTGTCCACTACTTCACCTTCAACCCCAGAGGAAAATGTTGGGTCCGAAGGCCAACCC
CCATGGGTCCAGGGACAGGACCTCAGTCCAGAGAAGTCTCTAGGGTCTAAAGTGGCTCAG
CTCAACAATACTTTGACCTGTGAGGTGATGGGACCTACCTCTCCCAAGATGAGACTGACC
CTGAAGCAGGAGAACCAGGAGGCCAGGGTCTCTGAGGAGCAGAAAGTAGTTCAAGTGGTG
GCCCCTGAGACAGGGCTGTGGCAGTGTCTACTGAGTGAAGGTGATAAGGTCAAGATGGAC
TCCAGGATCCAGGTTTTATCCAGAGGGGTGAACCAGACAGCAGTGGGGCTACTGGCTTTC
CTTGGTCTTCTTTTCTGCCTAGGGGTGGCCATG 
TTTGCTTACCAGAGCTGACTCGAG 
                   Stop    XhoI  
 
 
Sup.-Fig. 8b: Sequence of mouse CX3CL1/CD4 trunc (CD4 sequence in bold) 
mCX3CL1/CD4     
trunc_3.1+
mCX3CL1/
CD4 trunc
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